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IntroductIon
Mitochondria are abundant and dynamic organelles that not 
only produce ATP for cellular function, but also participate in a 
number of intracellular processes such as cell division, the initia-
tion of mitochondrial signaling pathways, modulation of cytosolic 
metabolic pathways, and modulation of cytosolic Ca2+ signals and 
concentration, and ultimately determination of cell life or death. In 
 addition, mitochondria are a continuous source of superoxide ani-
ons (O2
−) and their reactive oxygen species (ROS) products (Stowe 
and Camara, 2009; Camara et al., 2010b; Koopman et al., 2010), 
 particularly during cell injury. The rekindled interest in the organelle 
is ascribed in part to its role as a “friend and a foe.” This “new” role 
of mitochondria is crucial in understanding their utility as potential 
targets for therapies in mitigating diseases process.
Overall cellular function is dependent on O2 consumption by 
functioning mitochondria to produce energy with minimal electron 
leak to generate O2
−. Under physiological conditions, mitochondria 
exist in a metabolic and cellular ion homeostatic state that is crucial 
for normal myocardial function. Deviation from this physiological 
set-point can result for example, in abnormally high mitochondrial 
[Ca2+] (mCa2+) and increased oxidative stress. Oxidative damage to 
mitochondrial membranes, enzymes, and electron transport chain 
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duction, which facilitates mitochondrial permeability transition 
pore (mPTP) opening (Waldmeier et al., 2003) that leads to cellular 
apoptosis and necrosis. Therefore, increases in mCa2+ and ROS 
generation are two important underlying factors in the etiology 
of many disease states, notably cardiovascular diseases including 
heart failure, ischemia-reperfusion (I/R) injury, and other vascular 
disease processes. A salient observation of mitochondria-related 
diseases is that even though the fundamental pathological mecha-
nisms remain unclear, there is much evidence that mitochondrial 
dysfunction is a contributing factor at some level of every patho-
genic process (Duchen, 2004).
It is evident then that knowledge of mitochondrial function in 
normal and pathological states is crucial not only for our under-
standing of the basic cause of cardiovascular disorders, but also for 
developing therapeutic strategies for attenuating a given disease 
process. For example, attenuating electron transport, preventing 
mPTP opening (Wenzel et al., 2008), or activating the putative mito-
chondrial K+ channels (mitoKATP and mitoKCa), are potential ways 
to attenuate cardiac and vascular dysfunction by ameliorating the 
underlying mitochondriopathic disturbances (Doughan et al., 2008; 
Wenzel et al., 2008). The central premise of this review is simply that 
if mitochondrial abnormalities contribute to a pathological state (i.e., 
directly or indirectly), then alleviating the mitochondrial dysfunction 
should attenuate the severity or progression of the disease (Camara 
et al., 2010b). Hence, the main objective here is to present a concept 
that the mitochondria in all cells of the cardiovascular system can be 
potentially targeted for therapeutic intervention in treating cardio-
vascular diseases. This attention is warranted because cardiovascular 
diseases are a leading cause of death in the world. This review will 
focus in Part 1 on basic mitochondrial biology and its integration 
with the cytosol, metabolic regulation, structure and function, and 
the emerging yet essential role of mitochondria in cardiovascular 
disease in tandem with potential mitochondrial approaches for 
intervention. Separate sections on selected mitochondria therapeu-
tic approaches in specific cardiovascular maladies will be presented 
in Part 2, followed by limitations and conclusions.
Part 1
MyocardIal substrate MetabolIsM and regulatIon – 
IntegratIng cell and MItochondrIal functIon
Although this review emphasizes the important role of the mito-
chondrion in cardiovascular diseases and the emerging pursuit of 
mitochondrial-directed therapies, it is reasonable to first describe 
what is currently known about myocardial cell metabolism. Also, we 
would be remiss not to summarize the pioneering work of several 
research groups (Garland et al., 1963; Randle et al., 1963, 1970; Bing, 
1965; Opie, 1965; Williamson, 1965, 1966; England and Randle, 
1967; Bremer, 1969; Bremer and Wojtczak, 1972; Neely et al., 
1972; Oram et al., 1973; Neely and Morgan, 1974) who sought to 
understand the mechanical/metabolic integration of the cytosolic 
processes (energy use) with mitochondrial function (energy sup-
ply) during the basal cardiac state and during increases in cardiac 
workload, hypoxia and ischemia.
It is well known that phasic contractility and relaxation are 
dependent on the transient influx and efflux of Na+, K+ and Ca2+ 
to generate the action potential and trigger Ca2+ release from the 
sarcoplasmic reticulum (SR). The phasic increase and decrease in 
[Ca2+] with each heartbeat precedes each contraction and relaxation 
phase, which causes spikes in energy demand. How is this demand 
met? We now typically divide cardiac energy metabolism into three 
components (Neubauer, 2007) (1) substrate utilization [cell substrate 
uptake and fatty acid (FA) breakdown by β-oxidation and pyruvate 
by glycolysis yielding acetyl carbons on coenzyme A (CoA)], which 
enters into the TCA cycle to produce NADH, FADH2, and CO2), (2) 
oxidative phosphorylation (OxPhos, transfer of electrons from NADH 
to O2 by respiratory complexes I–IV to create a proton motive force 
required for ATP production at complex V, and (3) energy transfer and 
utilization [translocation of matrix ATP via the adenine nucleotide 
transporter (ANT) of the IMM and its conversion to phosphocrea-
tine (PCr) for transfer to myofibrils where it is reconverted to ATP 
by the creatine kinase (CK) energy shuttle system].
CK is a fast ATP-generating enzyme and a low-threshold sensor 
for ADP (Wallimann et al., 1992). Because mycoplasmic PCr is 
highly abundant, it serves as a temporal and spatial energy buffer-
ing transport system, which allows rapid ADP delivery for OxPhos 
with an increase in workload and a rapid absorption of ATP when 
workload decreases. Indeed the rate of ATP consumption is so 
exquisitely linked to the rate of oxidative phosphorylation that 
ATP, ADP, and PCr content remain nearly constant even when car-
diac workload increases during intense exercise or catecholamine 
release (Balaban et al., 1986). This suggested that consumption of 
ATP did not directly control ATP synthesis.
The hypothesis that ATP, ADP, CrP, and Pi are not the primary 
feedback regulators of OxPhos, e.g., during an increase in work-
load and O2 consumption, is based on numerous data that the 
concentrations of these compounds do not change significantly 
(Neely et al., 1972; Raymond and Potreau, 1977; Katz et al., 1989; 
Balaban, 1990), i.e., the metabolic stability hypothesis. So alter-
natively it was proposed, and some data was provided, that (a) 
increases in mCa2+ stimulate various rate – limiting TCA cycle 
enzymes (Wan et al., 1989; McCormack et al., 1990), i.e., the Ca2+ 
stimulating hypothesis, (b) the PCr shuttle acts as temporal and 
spatial buffers for the ATP hydrolysis potential, i.e., the PCr buffering 
hypothesis (Saks et al., 2000), and (c) that the activities of enzymes 
and transporters involved in ATP synthesis change in synchrony 
with, and proportional to, changes in the rate of ATP utilization so 
that perturbations can not be observed, i.e., the parallel activation 
theory (Korzeniewski et al., 2005). The alternative hypothesis to the 
metabolic stability hypothesis is of course that despite the negative 
experimental data generated, organic phosphates and Pi indeed 
regulate cardiac metabolism. Wu et al. (2007, 2008) developed a 
computer model of cardiac energy metabolism that was able to 
adequately simulate the data of Katz et al. (1989) but they arrived at 
a different interpretation, i.e., that ATP synthesis is indeed feedback 
controlled by an increase in the products of ATP hydrolysis (Beard, 
2006; Beard and Kushmerick, 2009). The simulations also agree 
with more recent experimental data (Ochiai et al., 2001; Zhang 
et al., 2005). The point here is that all hypotheses are subject to be 
disproven and alternate hypotheses should always be considered 
and tested even if the null hypothesis appears dominant.
Acetyl-CoA is the 2-carbon donor derived from FA or from glu-
cose oxidation. Complete β-oxidation of a 12-carbon FA produces 
96 mol ATP compared to 72 or 76 mol ATP by glycolytic oxidation 
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moderately increased glycolysis, marked fatty acid oxidation, and 
enhanced TCA cycle turnover, but not by changes in PCr, ATP, ADP, 
or 5′-AMP (later unequivocally verified by Balaban et al., 1986 using 
NMR). Although perfusion of hearts only with glucose exhibited 
marked pyruvate oxidation, those perfused with glucose+acetate 
showed inhibited glycolysis and inhibited pyruvate oxidation. They 
concluded that TCA cycle turnover was not solely dependent on 
the availability of a given substrate but that the normally preferred 
substrate was FA.
In a subsequent review, Neely and Morgan (1974) further 
described the regulation of substrate utilization and energy 
metabolism in the heart. They pointed out that the availability 
of higher energy FA in aerobic perfused hearts suppressed lower 
energy glucose utilization at several steps in the glycolytic pathway, 
i.e., blocked glucose transport, inhibited hexokinase by its product 
glucose-6-P, phosphofructokinase (PFK) by citrate (Garland et al., 
1963; England and Randle, 1967), and pyruvate dehydrogenase 
(PDH) by acetyl-CoA and NADH (Bremer, 1969; Randle et al., 
1970). They described how FA uptake and oxidation are control-
led by FA availability, the rate of acetyl-CoA oxidation (low energy 
rates), and the rate of acyl translocation across the IMM (high 
energy rates), which in turn is dependent on the activity of CPT. 
They discovered that at higher workloads acetyl-CoA levels were 
progressively decreased and concluded that FA oxidation becomes 
limited (Oram et al., 1973); they suggested that acyl transloca-
tion and transfer to matrix CoASH or CPT activity, rather than 
β-oxidation, was the limiting step to FA utilization. They discussed 
how the NAD-linked dehydrogenase reactions of the TCA cycle 
ultimately determine the rates of oxidation of both glucose and 
FA and adjust the rate of utilization of each substrate to the avail-
ability of the other.
Although the preferred substrate for the heart was found to be 
FA (80–100%), Neely and Morgan (1974) discussed that under 
hypoxic or anoxic conditions the heart switches primarily from 
FA to glucose; but under ischemic conditions the switch to glucose 
is limited due to shortage of substrate. They also indicated that a 
hypoxia/ischemia-induced rise in NADH inhibits glyceraldehyde-
3-P dehydrogenase thus restricting glycolysis. During I/R, dimin-
ished O2 supply for respiration and OxPhos leads to rapid decline 
of ATP and PCr, and the concomitant increase in Pi, as a conse-
quence of PCr hydrolysis, stimulate anaerobic ATP generation with 
an increase in glycolysis and lactate production (Oram et al., 1973; 
Wallimann et al., 1992). Whitmer et al. (1978) later reported that 
decreased O2 delivery to the heart caused a fall in tissue content 
of acetyl-CoA, acetyl-carnitine, CoASH, and carnitine, indicating 
that β-oxidation becomes limited under these conditions. Thus 
the heart has the ability to switch from FA to glucose oxidation 
during anaerobic metabolism, which yields substrate (cytosolic) 
level phosphorylation (2 mol ATP/mole glucose when pyruvate 
is formed from phosphoenolpyruvate) on its pathway to form 
acetyl-CoA.
In a 1979 review Williamson (1979) discussed how feedback 
regulation from the TCA cycle and the respiratory chain to PDH is 
likely determined primarily by alterations of the intra-mitochon-
drial NADH/NAD+ and acetyl-CoA/CoASH ratios acting separately 
or in concert, and not by the intra-mitochondrial ATP/ADP ratio 
of a 12-carbon disaccharide. The different moles of ATP produced 
by glycolysis depends on the use of the glycerol phosphate shut-
tle vs. the malate shuttle, respectively, which transfers reducing 
equivalents from the cytosol to the matrix where they are oxidized 
to produce energy. This transfer is slow and rate limiting in gly-
colysis so mitochondrial FA oxidation is much faster (Williamson 
et al., 1976; Saks et al., 2006b). The major task of the TCA cycle is 
to carry out the oxidation of the acetyl group of acetyl-CoA to CO2 
and H2O with the subsequent production of reducing equivalents 
to maintain the proton motive force and energy transfer from elec-
trons to drive ATP synthesis.
Indeed, from earlier work (Williamson, 1965, 1966) it is now 
well understood (Saks et al., 2006b) that during an increase in 
workload, ATP production and respiration are increased due to 
feedback signaling via the CK shuttle that leads to a decrease in 
the mitochondrial content of acetyl-CoA. This decrease reflects 
increases in the rates of respiration and NADH oxidation relative 
to acyl-carnitine transport into mitochondria and β-oxidation. It 
is now known that acetyl-CoA is transferred into the cytoplasm 
during high workloads via the carnitine-acetyl carrier where it is 
converted by acetyl-CoA carboxylase (ACC) to malonyl-CoA, an 
important inhibitor of carnitine-acetyl-CoA (palmitoyl) trans-
ferase (CPT), and then converted back to acetyl-CoA by malonyl-
CoA decarboxylase (MCD) during reduced workloads. Therefore, 
an increase in workload increases the rate of acetyl-CoA consump-
tion with a concomitant increase in malonyl-CoA content. This 
mechanism prevents excess FA β-oxidation intermediates when 
the workload decreases. This implies that malonyl-CoA is a feed-
back regulator of FA oxidation by allowing acyl-CoA entry into the 
matrix only when it is needed (Opie, 1998). Thus the decrease in 
malonyl-CoA (and increase in acetyl-CoA) is not the reason, but 
rather the consequence of an increase in workload and FA oxida-
tion (Saks et al., 2006b).
In broad terms this process of multiple feedback steps in regulat-
ing substrate utilization, OxPhos, and energy transfer and utiliza-
tion at varying workloads, is called metabolic homeostasis, and 
its study, metabolic control analysis. Identifying the specific rate 
controlling reactions is cumbersome and typically carried out by 
measuring depletion of substrates and accumulation of products 
and their associated flux rates. Stanley et al. (2005) and Neubauer 
(2007) have reviewed recently how substrates are metabolized by 
mitochondria in the normal and failing heart. Metabolic Control 
Analysis is a methodology that allows one to quantitate the con-
trol of flux and metabolites through a metabolic pathway (Kacser 
and Burns, 1973; Heinrich and Rapoport, 1974; Fell, 1992). This 
approach has been applied to a great variety of systems – from 
bacteria to mammalian and plant cells – functioning at steady state 
(Fell, 1996; Cortassa et al., 2002) but recently also to heart cells 
and trabeculae under working conditions (Cortassa et al., 2009).
cardIac MetabolIc control – hIstorIcal PersPectIve
Randle et al. (1963) long ago first recognized that cells utilize 
either FA or glucose depending on substrate availability and that 
the presence of FA markedly inhibits glycolysis; this is known as 
the glucose–fatty acid cycle or the “Randle cycle.” It has been long 
known that FAs contain more energy per mass unit than glucose 
(Newsholm and Start, 1973). Neely et al. (1972) were among the first 
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key to understanding the molecular mechanisms of many disease 
states, and it also opens the possibility of therapeutic intervention 
by targeting the imported proteins or their translocases.
outer MItochondrIal MeMbrane as a target for PotentIal 
theraPeutIc agents
The elaborate structure of a mitochondrion is important for its nor-
mal functioning, so its structural elements are potential therapeutic 
targets. Each mitochondrion consists of two specialized membranes 
dividing the organelle into a narrow intermembrane space (IMS) 
bordered by the outer mitochondrial membrane (OMM) and the 
inner mitochondrial membrane (IMM) that encloses the matrix 
(Figure 1). The OMM is a relatively simple phospholipid structure 
permeable to small molecules and ions; it contains many proteins 
including monoamine oxidase (MAO) and the voltage dependent 
anion channel (VDAC).
The OMM is also a major source of ROS and MAO (mostly 
the A isoform), with a large presence in the OMM, contributes to 
the ROS generated by mitochondria under pathological condi-
tions. The MAOs are mitochondrial flavoenzymes that catalyze 
the oxidative deamination of catecholamines and biogenic amines, 
like dopamine, and serotonin (5-HT). In the process, ROS (H2O2 
from O2
−) is generated (Kaludercic et al., 2010a,b), which exert 
hypertrophic effects or aggravate I/R injury (Kaludercic et al., 
2010a; Nediani et al., 2011). During I/R or heart failure, the heart 
is exposed to chronic neuro-hormonal or peripheral hemodynamic 
distress and this leads to elevated circulating catecholamines, result-
ing in MAO-induced ROS production. In the heart, it has been 
reported that 5-HT accumulates during I/R and contributes to 
the progression of myocardial damage and injury independent of 
5-HT receptor mediated activity (Bianchi et al., 2005), and in the 
kidney MAO-induced H2O2 production during dopamine degrada-
tion was reported to mediate cell apoptosis (Bianchi et al., 2005). 
A possible mechanism for MAO-mediated cell death is that MAO-
dependent ROS generation induces an increase in the Bax/Bcl-2 
ratio and mitochondrial cytochrome c release, leading to cardiac 
cell apoptosis (Bianchi et al., 2005). In a recent study, Kaludercic 
et al. (2010b) reported that in addition to 5HT, NE catabolism 
by MAO plays a prominent role in cardiac hypertrophy. In their 
study, Kaludercic et al. (2010b) reported that MAO enhanced NE 
metabolism in transverse aortic constriction in mice, which was 
also associated with exacerbated oxidative stress, chamber dilation, 
and reduced systolic function. These observations provide evidence 
for the pivotal role that mitochondrial MAO has in these disease 
processes and provides a therapeutic potential for their inhibition. 
The targeting of mitochondrial MAO for its potential therapeutic 
effect derives in part from the finding that MAO inhibition can 
counteract oxidative stress and mitochondrial-induced cell death 
while reducing myocardial damage due to I/R injury (Bianchi et al., 
2005; Morin et al., 2009).
The VDAC is a principal site for the exchange of metabolites 
between the IMS and the cytosol. The VDAC is a regulated conduit 
that provides an access route into the IMS for ions and a vari-
ety of cellular metabolites such as ATP and ADP (Okada et al., 
2004). Decreased phosphorylation of VDAC, which is induced 
by inhibition of glycogen synthase kinase, can reduce ATP entry 
because this did not appear to change appreciably with changes in 
cardiac activity, as noted by others. He noted that the malate shut-
tle is slow and limits maximal glucose oxidation. He additionally 
described how the activities of NAD-linked TCA enzymes pyru-
vate dehydrogenase, α-ketoglutarate dehydrogenase, and isocitrate 
dehydrogenase are regulated by the NADH/NAD+ ratio. As this ratio 
decreases with increased workload, and the cytosolic ATP/ADP 
ratio tends to fall and Pi to increase at the expense of PCr, respira-
tion increases, thus increasing the flux of TCA cycle intermediates 
(just enough acetyl-CoA enters the matrix (Saks et al., 2006b) with 
increases in FA and/or glucose oxidation, which is highly regulated 
by feedback mechanisms. There are other excellent older and newer 
reviews (Bing, 1965; Williamson, 1979; Opie, 1998; Randle, 1998; 
Nicholls and Fergunson, 2002) and original articles (Garland et al., 
1963; Williamson, 1965, 1966, 1979; England and Randle, 1967; 
Bremer, 1969; Bremer and Wojtczak, 1972) that summarize and 
update this seminal early work on cardiac metabolic homeostasis.
MItochondrIal dna and ProteIn transPort as sItes for 
theraPeutIc InterventIon
Mitochondrial biogenesis and regulation of mitochondrial func-
tion result from a complex process that involves the coordinated 
expression of both mitochondrial and nuclear genes (Camara et al., 
2010b). Much of the mitochondrial DNA (mtDNA) is used to code 
for proteins that are key components of the energy-production 
system. Indeed, mitochondrial DNA contributes 13 subunits to 
ETC complexes. Cells depleted of mtDNA, called r0-cells, lack 
some of the critical subunits of the ETC complexes, which result 
in a defective respiratory system as evidenced by an insufficient 
mitochondrial membrane potential (∆Ψm; Camara et al., 2010b). 
The nucleus regulates numerous mitochondrial functions because 
the nuclear DNA (nDNA) encodes a majority of mitochondrial 
proteins. For example, complexes I and III are coded by the nDNA 
and the mtDNA (Papa et al., 2008) whereas complex II is coded 
only by nDNA. Several complex IV subunits, depending on the 
tissue type, are also mitochondria-derived (Lenka et al., 1998; 
Vijayasarathy et al., 1998). The mitochondrial proteins coded by 
the nuclear genome promote increased synthesis of mitochondrial 
encoded proteins and replication of mtDNA (Duchen, 2004). For 
example, the nuclear respiratory factor-1 activates the transcrip-
tion of a number of the nuclear-encoded components of the ETC 
and also regulates mitochondrial transcription factor A, which is 
responsible for the transcription of mtDNA-encoded genes (Csiszar 
et al., 2009b).
  Nuclear-encoded proteins targeted for mitochondria are 
imported by a complex system of import proteins (TOM and 
TIM, outer and inner membrane translocases, respectively). Import 
of nuclear-encoded proteins or precursor peptides relies on the 
proper function of the mitochondrial protein uptake machinery. 
A coordinated protein import system is important for mitochon-
drial maintenance and biogenesis and any disruption can lead to 
cell dysfunction and demise, including cells in the cardiovascular 
system (Duchen, 2004). The protein import pathway has been used 
to direct proteins into mitochondria based on specific targeting 
sequences (Schapira, 2006). A defect in a specific protein or damage 
to the import system can contribute to other defects in mitochon-
drial function and underlie at least some cardiovascular disorders. 
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removal if cell death is required, as in cancer cells (Camara et al., 
2010b). Indeed, in malignant tumor cells, unlike normal cells, ele-
vated oncogenic kinase signaling favors the binding of HK to VDAC 
by Akt-dependent phosphorylation of HK (Pastorino et al., 2005). 
Enhanced association between HK and VDAC provides protection 
against permeabilization of the OMM and resistance to apopto-
sis (Galluzzi et al., 2008; Pastorino and Hoek, 2008). However, it 
is noted that the binding to the VDAC is not a prerequisite for 
HK binding to OMM because the enzyme binds to OMM in yeast 
strains that are deficient in VDAC (Shoshan-Barmatz et al., 2008).
Nonetheless, a possible therapeutic strategy that targets mito-
chondrial metabolism involves enhancing HK–VDAC interactions. 
For example, it was reported that closure of VDAC by HK prevents 
mPTP opening and blocks apoptosis (Azoulay-Zohar et al., 2004). 
Other studies show that increased HKII binding to VDAC pre-
vents the pro-apoptotic Bcl-2 family proteins from binding to the 
OMM, and so helps to promote, for example, cancer cell survival 
(Costantini et al., 2000; Gogvadze et al., 2009; Mathupala et al., 
2009). Indeed, HK is frequently overexpressed in some human 
tumors and it binds to VDAC more tightly in cancer cells than in 
their normal cell counterparts (Pastorino et al., 2005). This pro-
tection may be prevented, as a therapeutic approach, by adding 
3-bromopyruvate, an inhibitor of HK activity and HK binding to 
into mitochondria (Das et al., 2008). As a major gateway in and 
out of the mitochondrion, VDAC mediates an intimate dichot-
omy between metabolism and cell death (Ujwal et al., 2008). The 
mitochondrial-mediated cell death pathway involves an array of 
OMM and cytosolic proteins that include the hexokinases (I and II), 
the 4-chlorodiazepine (CDZ) sensitive peripheral benzodiazepine 
receptor (PBR), and the Bcl-2 protein family that alternatively pro-
mote or prevent cell injury (Bryson et al., 2002; Pastorino et al., 
2005; Pastorino and Hoek, 2008; Ujwal et al., 2008). Specifically, 
PBR interacts with mPTP through VDAC and regulates apoptosis as 
it blocks the anti-apoptotic effect of Bcl-2 family proteins (Kroemer 
et al., 2007). CDZ reduces ischemia-induced arrhythmias and cyto-
chrome c release independent of mPTP opening by inhibiting PBR 
(Camara et al., 2010b). Perfusion of rat hearts with a cell-permeable 
peptide corresponding to the BH4 domain of Bcl-XL, which is 
reported to close VDAC and to prevent the VDAC-mediated release 
of cytochrome c, was shown to inhibit CK release and to reduce 
myocardial cell death (Morin et al., 2009). Thus the OMM sup-
ports protein-to-protein interactions between the anti-apoptotic 
and pro-apoptotic proteins.
The hexokinase (HK)-VDAC is another OMM protein-to-pro-
tein interaction that offers an intriguing target to selectively provide 
cytoprotection against oxidative damage. Accumulating evidence 
has shown that HK translocation to mitochondria plays a crucial 
Figure 1 | The figure shows the basic structural components of the eTC 
complexes (i, ii, iii, iV, and V) the sites of proton pumping after electron 
transfer from complex i and complex ii during mitochondria substrate 
oxidation, that leads to the generation of ATP . Fatty acid oxidation and 
Krebs cycle generate NADH and FADH2 needed to energize mitochondria 
and establish the mitochondrial membrane potential (∆Ψm; −180 to 
−200 mV). The ∆Ψm can be modulated be uncoupling proteins (UCP). 
Phosphate is imported and exported through the adenine nucleotide 
translocase (ANT) and this is one way to regulate matrix phosphate levels. 
Substrate uptake is mediated through mitochondrial inner membrane (IMM) 
proteins [e.g., carnitine palmitoyl transferase (CPT) and pyruvate 
dehydrogenase (PDH)]. Ca2+, which may modulate mitochondrial respiration 
is taken up via the calcium uniporter (CaU). Other components of the IMM 
include the putative transporters/exchangers. These include the Na+/H+ 
exchanger (NHE), the K+/H+ exchanger (KHE) and the Na+/Ca2+ exchanger 
(NCE), some of which have been characterized. The putative Ca2+/H+ 
exchanger (the so-called Na independent Ca exchanger or NICE; not shown) 
is considered a likely regulator of ion flux dynamics.
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to preserve cytochrome c (Vlasova et al., 2006). Indeed, in a com-
prehensive study, Vlasova et al. (2006) reported that NO
 acts as 
an effective inhibitor of peroxidase activity on the cytochrome 
c-cardiolipin complex, and in this way preserves cardiolipin integ-
rity. The authors observed that NO
 acted as an effective inhibitor 
of the peroxidase activity of cytochrome c without significantly 
altering the cardiolipin molecule itself. Similarly, the dominant 
antioxidant effect of NO
 on the peroxidation reaction catalyzed 
by myoglobin and hemoglobin is reduction of oxo-ferryl reac-
tive species (Gorbunov et al., 1995). This observation along with 
those by Shidoji et al. (1999) showed that cardiolipin peroxidation 
products resulted in a lack of effective binding of cytochrome c 
to cardiolipin. This suggests that reducing the catalytic peroxi-
dase activity of the complex by NO
 reduces the hydroperoxide 
products that enhance peroxidation of the lipid. It is therefore 
likely that NO
 prevents the oxidation of cardiolipin in part by 
inhibiting the damaging effects of the peroxidase activities of the 
cytochrome c-cardiolipin complex that occurs during ischemia 
and other oxidative stress. Thus, inhibiting the peroxidase activ-
ity of the complex may be a pathway by which NO
 attenuates 
cardiolipin oxidation (Shidoji et al., 1999); it is also reported that 
NO
 could be an effective scavenger of peroxyl and other radicals 
(Chamulitrat, 2001). These observations indicate that the cyto-
chrome c-cardiolipin peroxidase complex is an important factor 
in oxidative-mediated damage and represents a viable option to 
be considered in targeting mitochondria therapeutically.
The adaptor protein p66Shc is an IMS protein located in the ETC 
segment between complex III and IV. The regulation of p66Shc is not 
fully understood. At physiological states, the protein is silent but is 
activated in response to pro-apoptotic stimuli. Recent studies have 
shown that p66Shc is involved in e− transfer with reduced cytochrome 
c, and so it can modulate ROS production and the cardiovascular 
oxidative stress response (Shoshan-Barmatz et al., 2008; Camara 
et al., 2010b). Mitochondrial p66Shc can be induced, for example, 
by hypertrophic stimuli and it is a signaling link between cellu-
lar stress and mitochondrial apoptotic activity (Guo et al., 2009). 
Activation of the protein occurs via H2O2 dependent phosphoryla-
tion of the Ser36 residue, with its ultimate translocation to mito-
chondria. Once in mitochondria, p66Shc also alters mCa2+ handling, 
and ultimately can induce apoptosis (Pinton et al., 2007). In addi-
tion to stimulating release of ROS, p66Shc can decrease MnSOD 
expression levels by activating the Akt-dependent phosphorylation 
of Forkhead transcription factor (FOXO3a) pathway, a regulator 
of MnSOD expression. Consistent with these mechanisms, mice 
deficient in mitochondrial p66Shc genes display increased levels of 
FOXO3a, and decreased ROS production and decreased cardiac 
I/R injury (Carpi et al., 2009; Di Lisa et al., 2009).
It was proposed recently that the therapeutic targeting of ETC 
complex IV as a strategy to mitigate I/R injury may worsen outcome 
in part because of the increased levels of reduced cytochrome c 
(Chen et al., 2010), a substrate for p66Shc mediated ROS generation. 
It is possible that pharmacological therapies that inhibit mitochon-
drial p66Shc expression or action may act as panacea for clinical 
disorders characterized by increased oxidative stress, e.g., athero-
sclerosis, I/R injury and cardiac heart failure. However, Di Lisa et al. 
(2009) noted in a recent review that at present the   translation of 
mitochondria, the latter most likely by preventing the HK-VDAC 
interaction (Pedersen et al., 2002; Chen et al., 2009). In non-malig-
nant conditions, partial knockout of HKII has been associated with 
increased cell death in a mouse model of cardiac I/R injury (Smeele 
et al., 2010). For the heart it is suggested that the mitochondria-
HK interaction is indeed an integral part of cardioprotection 
because many cardioprotective interventions, such as ischemic 
preconditioning (IPC) and anesthetic preconditioning, increase 
mitochondria-HK binding (Zuurbier et al., 2009). The transloca-
tion and increased binding of HKII to cardiac mitochondria can be 
invoked in the mechanism of cardioprotection by IPC and opioids 
(Smeele et al., 2010). HKII binding to mitochondria to decrease 
pro-apoptotic Bcl-2 family protein binding to OMM, as well as 
decreasing ROS production may contribute together to improving 
mitochondrial and cell function during reperfusion after ischemia.
Taken together, these studies suggest that the mitochondrial HK 
interaction plays a key role in promoting cellular survival; thus tar-
geting its binding to the mitochondrion may offer a novel strategy 
to potentiate the efficacy of other modes of cardiovascular inter-
vention. A mitochondria-targeted therapy designed for the OMM 
as a potential therapeutic maneuver is highly relevant and is the 
subject of intense research. An understanding of the interaction 
between the cytosolic proteins, glycolytic or apoptotic, and the 
OMM should help to optimize therapies for treating degenerative 
diseases, including ischemic heart disease and heart failure. These 
mitochondrial related diseases and the potential targeting of the 
organelle as a mitigating factor will be discussed in detail in the 
coming sections.
Inner MItochondrIal MeMbrane and MatrIx as sItes for 
PotentIal theraPeutIc agents
The IMM is convoluted into a large number of infoldings called 
cristae. As a consequence, the IMM has a large surface area that 
increases the efficiency of the chemical reactions that take place 
at its inner surface (Koopman et al., 2010). The IMM is relatively 
impermeable and allows only certain small molecules (ions mostly) 
to pass through. The major phospholipid component of the IMM, 
cardiolipin, is intimately involved in several mitochondrial bioener-
getic functions as well as in the regulation of cytochrome c content 
and function. IMM proteases, by targeting mitochondrial fusion 
proteins (discussed below), also regulate the release of cytochrome 
c release from mitochondria (Frezza et al., 2006). Apoptosis induc-
ing factor (AIF) is also released from the IMM, but by proteo-
lytic cleavage catalyzed by mitochondrial calpain and preceded by 
mitochondrial ROS emission (Norberg et al., 2010). I/R mediated 
cell death can be prevented by calpain inhibitors and by MnSOD 
(Norberg et al., 2010). Damage to cardiolipin has been implicated 
in numerous pathological conditions, including cardiovascular 
abnormalities.  Paradies et al. (2009) reported that cardiolipin 
content observed in mitochondria from I/R hearts paralleled the 
fall in complex I activity.
Cardiolipin and cytochrome c can form into a complex called 
cytochrome c-cardiolipin peroxidase, which under oxidative stress 
and oxidation of cardiolipin can lead to the release of cytochrome 
c and other pro-apoptotic factors from the IMS to the cytosol 
(Chen et al., 2010). Therefore, targeting this complex, as demon-
strated with nitric oxide (NO
), has proven somewhat valuable in 
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high m[Ca2+], as observed during cardiac I/R, can impair ATP syn-
thesis and lead to a loss of ion homeostasis, stimulation of ROS 
generation, mPTP opening, matrix swelling, and OMM rupture 
(Jones et al., 2003; Teshima et al., 2003b). Cumulatively, all these 
factors result in collapse of ∆Ψm, release of signaling molecules 
(cytochrome c, AIF, and Smac/Diablo), and exacerbation of ROS 
production, resulting in a catastrophic vicious cycle of mitochon-
drial functional decline, and ultimately cell death (Brookes et al., 
2004; Muravchick and Levy, 2006). This subject matter along with 
the role of other mitochondrial proteins intimately involved in 
regulating mitochondrial free ion concentrations and matrix pH, 
have been discussed extensively in our recent comprehensive review 
article (Camara et al., 2010b).
It is important to note that the ∆Ψm is about two times larger 
than the sarcolemmal membrane potential. This provides a unique 
chemical opportunity for selectively targeting the mitochondrion 
for therapeutic purpose. In fact, this unique attribute of mito-
chondria has been employed to direct the so-called “mitochon-
driotropic” drugs to target the matrix (Brookes et al., 2004). For 
example, Smith et al. (1999) reported that complexing vitamin 
E with the triphenyl-phosphonium (TPP+) cation augmented 
mitochondrial uptake of the complex. The cationic metallopor-
phyrin superoxide dismutase mimetic Mn (III) meso-tetrakis 
(N-ethylpyridium-2-yl) porphyrin (MnIII TE-2-Pyp5+) has been 
shown to accumulate in mitochondria derived from mice cardiac 
myocytes following systemic injection (Spasojevic et al., 2007). We 
have shown that mitochondrial superoxide (O2
−) production and 
heart damage resulting from prolonged cold I/R was attenuated 
when the permeant MnSOD mimetic manganese (III) tetrakis 
(4-benzoic acid)porphyrin (MnTBAP) was perfused into the coro-
nary arteries along with catalase and glutathione (GSH) before 
ischemia (Camara et al., 2010b). However, the effectiveness of 
these drugs to mitigate cardiovascular abnormalities in the clinical 
setting has yet to be determined.
MItochondrIal PerMeabIlIty transItIon Pore oPenIng as a 
PotentIal theraPeutIc target
A key aspect of mitochondrial involvement in cell demise is control 
of the opening of the mPTP. Crompton et al. (1987) were the first 
to report that mPTP opening plays a crucial role in myocardial I/R 
injury. The mPTP is a highly dynamic, non-selective pore for which 
the precise structural identity is not well defined. Suffice it to state, 
however, that the pore is thought to span the OMM and the IMM 
and that it mediates the lethal permeability changes of the IMM and 
OMM that leads to cell apoptosis. The mPTP may allow limited and 
transient passage of electrolytes, small molecules, and metabolites. 
But irreversible opening of the pore leads to release of apoptotic 
protein factors (Kim et al., 2003; Martinez-Ruiz et al., 2008; Sun 
et al., 2008), and a loss of NAD+ results in impaired capacity to 
restore redox signaling and O2
− scavenging (Di Lisa et al., 2001). A 
detailed description on the putative constituents and functionality 
of the pore, physiological or pathophysiological, has been discussed 
in our recent comprehensive review article (Camara et al., 2010b) 
and so will not be discussed further here. Indeed, mPTP opening is 
especially sensitive to oxidative stress since it is favored by decrease 
in NADPH/NADH and GSH/GSSG ratio (Di Lisa et al., 2009).
experimental findings into the clinical realm is limited by the lack 
of drugs that might be effective against a direct p66Shc mediated 
ROS production.
The IMM also contains the adenine nucleotide translocator 
(ANT), which along with VDAC, is believed to play a role in the 
formation, or more likely, the regulation of the mPTP. The ANT 
has been shown to be a prominent target for oxidative and nit-
rosative stress and so appears to be an important component in 
mitochondria-related cell death and diseases. ANT interacts with 
both the anti-apoptotic and pro-apoptotic BCl-2 protein families, 
which then act as allosteric modulators of the ATP/ADP anti-por-
ter (Marzo et al., 1998; Brenner et al., 2000; Belzacq et al., 2003). 
Another potential binding partner of ANT is mitochondrial crea-
tine kinase (mCK), which together with other enzymes is part of a 
phosphotransfer network that is crucial for the coupling of OxPhos 
with ATP-consuming processes (Saks et al., 2006a). Enhancing 
phosphotransfer from ATP to creatine in close proximity to ANT 
may be beneficial in preventing mPTP opening and reducing ROS 
production under stress conditions (Dolder et al., 2003; Meyer et al., 
2006). The underlying mechanism may be the result of conforma-
tional changes in ANT and a more state 3 like respiration due to 
increased ADP production. A therapeutic approach could involve 
the design of creatine analogs that would increase the turnover 
of ATP to ADP in proximity to ANT. Disruptions of ANT activ-
ity, on the other hand, can result in inhibition of ATP/ADP anti-
porter activity, excess ROS production, cytosolic ATP depletion, 
and mitochondria depolarization and apoptosis (Don et al., 2003). 
Clinically, dysfunction of ANT has been proposed to be involved 
in dilated cardiomyopathy (Dorner et al., 1997). Thus, preserving 
ANT functional integrity may provide a unique opportunity for 
pharmacological or molecular genetic maneuvers that target this 
protein to preserve mitochondrial function during cell injury.
Under physiological conditions, mitochondria exhibit a high 
IMM potential (∆Ψm) that is initiated by proton pumping from 
the matrix with simultaneous e− transfer along the ETC; ∆Ψm is 
also maintained by various cation channels and exchangers that 
regulate cation fluxes. The trans-membrane cation movement 
through specialized cation transporters and exchangers are there-
fore essential for creating the resulting mitochondrial bioenergetic 
state (Figure 1). Mitochondrial cation anti-porters/exchangers 
(H+-linked) regulate the osmotic differential across the IMM. This is 
necessary in part because of a low cationic permeability and a strong 
H+ electrochemical gradient that is established by e− transfer and 
cation exchangers to prevent osmotic overload; these conditions are 
necessary for efficient OxPhos (Camara et al., 2010b). The trans-
membrane cation movement through specialized cation transport 
and exchangers is therefore essential for creating the resulting mito-
chondrial bioenergetic state (Figure 1).
Alterations in the dynamic regulation of ion fluxes underlie 
numerous abnormalities of mitochondrial related function. For 
instance, mCa2+ uptake through the Ca2+ uniporter (CaU) is largely 
dependent on ∆Ψm. This mCa2+ uptake may have profound conse-
quences for mitochondrial function, such as altering cellular res-
piration and mediating cell death by apoptosis or necrosis (Sack, 
2006a; Camara et al., 2010b). A small increase in mCa2+ during 
increased workload is thought to be necessary for activating TCA 
cycle enzymes to furnish the reducing equivalents necessary to 
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and is accompanied by depressed ETC function in the setting of FA 
accumulation and loss of cytochrome c and ROS scavengers; and (ii) 
the triggering of mPTP at reperfusion as determined by the inter-
play of ∆Ψm with rising mCa2+, with ROS and matrix H+ (Honda 
et al., 2005). During ischemia pore opening is minimized, but on 
reperfusion conditions such as increased matrix Ca2+, Pi, and ROS 
favor long-lasting pore opening. Sustained and prolonged opening 
of the mPTP can lead to excessive H2O entry into the matrix, matrix 
swelling, and increased OMM permeability (via oligomerization 
of Bid or Bax) or rupture of the OMM and IMM. Figure 3 sum-
marizes the deleterious changes in mitochondrial function during 
and after cardiac I/R associated with mPTP opening, permeabiliza-
tion of the OMM, and changes in bioenergetic state associated with 
individual components of mitochondria that are potential targets 
for therapeutic intervention.
As noted the exact molecular composition of the mPTP remains 
elusive and mysterious. The previous model structure of the mPTP 
put forward by Halestrap (2010) and Di Lisa and Bernardi (2006) 
involves the combination of the ANT in the IMM, the VDAC in 
the OMM, and the regulatory protein cyclophilin D (CypD) in the 
As noted above, recent evidence suggests that at low  conductance 
states the pore might contribute to the exchange of small metabo-
lites between the cytosol and matrix, a process that is mainly con-
trolled by mitochondrial solute carriers (Fulda et al., 2010). In this 
case the opening of the pore is considered a “physiological valve,” 
which alleviates mCa2+ overload, for example, as a consequence 
of a brief surge of Ca2+ within a localized microdomain of the 
mitochondria–endoplasmic reticulum (Smaili and Russell, 1999) 
(Figure 2). Mitochondria play an essential role in buffering physi-
ological loads of Ca2+ upon insult, whereas the mPTP provides a 
fast Ca2+ extrusion mechanism in response to excessive levels of Ca2+ 
(Sareen et al., 2007). In addition, the brief opening and closing of 
the pore (flickering) are implicated in providing protection against 
cellular injury (Kindler et al., 2003). This dual role of the mPTP in 
the survival and death of the cell will therefore be critical in selective 
targeting of the pore for therapeutic interventions.
Pathologically, mPTP opening is initiated by excess mCa2+, 
enhanced ROS production, and increased Pi. Adenine nucleotides, 
Mg2+, and matrix H+ restrict the pore from opening (Brookes et al., 
2004; Duchen, 2004; Halestrap et al., 2004, 2007; O’Rourke, 2007). 
It is proposed that I/R promotes mPTP opening in two phases: (i) 
Figure 2 | interaction between mitochondria and Sr Ca2+-release channels. 
This structural arrangement allows mitochondria and SR to be connected by tether 
proteins (not shown), which allows regulation of matrix Ca2+ that may modulate 
mitochondrial activity. Mitochondria take up Ca2+ ions entering the cytosol from 
internal stores (SR) of the local “microdomain” via signaling molecules that include 
Ca2+ and ROS. After cell stimulation, inositol 1,4,5-trisphosphate (IP3) and cADP 
ribose (cADPr) release calcium from SR through their respective receptors [IP3R 
and ryanodine receptors (RyR)]. Local increases in cytosolic Ca2+ concentrations 
are buffered by mitochondrial uptake through the calcium uniporter (CaU) and 
possible alternative routes, such as the putative Ca2+/H+ exchanger [the so-called 
Na+ independent Ca2+ exchanger (NICE, or CHE); not shown]. Intra-mitochondrial 
Ca2+ may activate synthesis of reduced substrates (NADH) by metabolic pathways 
and accelerate the electron transport chain (ETC); a resulting increase in ROS 
production may in turn facilitate Ca2+ release by sensitization of IP3R and RyR. The 
increase in respiration is associated with enhanced proton pumping and 
subsequently increase state 3 respiration with perhaps increase CHE activity so 
that more Ca2+ is taken up from the localized “microdomain. ” Other putative 
mechanisms that increase ROS generation are modifications of ETC complexes 
by mCa2+ and inhibition of the ETC by nitric oxide (NO
). The NO
 can be increased 
by Ca2+-induced NO
 synthase. Mitochondrial can also support Ca2+ release by 
efflux via Na+/Ca2+ exchange (NCE). The delicate balance in the regulation of Ca2+ in 
the “microdomain” is crucial in the pathology of mitochondria-related 
cardiovascular complications. Reproduced and modified by permission from 
Camello-Almaraz et al. (2006).
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associated with numerous pathological conditions, e.g., stroke 
accompanied by brain ischemia (Matsukawa et al., 2009). These 
actions of the mPTP apply in most instances of cell damage and 
suggest that pharmacological agents, or any other maneuvers that 
minimize pore opening, might minimize the extent of permanent 
damage that arises. For example, Pravdic et al. (2010) reported 
recently that in vivo isoflurane-induced post-conditioning pre-
vented mPTP opening in part by mild inhibition of mitochon-
drial respiration, depolarization of mitochondria, and acidification 
of matrix pH. These events may lead to better preservation of 
mitochondrial bioenergetics and minimize Ca2+ overload and cell 
death (Pravdic et al., 2010). Another example is that melatonin, a 
well-known antioxidant, has also been shown to protect against 
reperfusion injury by inhibiting mPTP opening (Petrosillo et al., 
2009) (Figure 3). In this case, mitochondria isolated from rat hearts 
exposed to melatonin before I/R were less sensitive than mito-
chondria isolated from control I/R hearts to mPTP opening as 
demonstrated by their resistance to Ca2+-induced pore opening. 
CsA, the well-known inhibitor of mPTP opening, had effects similar 
to melatonin (Petrosillo et al., 2009).
In a recent limited human clinical trial it was suggested that 
CsA can reduce infarct size and improve recovery of contractile 
function on reperfusion (Gomez et al., 2009). The antidepressant 
drug nortriptyline was also reported to exert its neuroprotective 
effects against cerebral I/R injury in part by delaying mPTP opening 
matrix (Camara et al., 2010b). In addition, a benzodiazepine recep-
tor, HK, and mitochondrial mCK are thought to act as regulatory 
components of the pore (Honda et al., 2005). Associated with the 
outer leaflet of the IMM, in the IMS, is the CK. As mentioned earlier, 
mCK, under physiological conditions, is crucial in catalyzing the 
transphosphorylation of creatine by ATP to phosphocreatine and 
ADP. In apoptotic-induced cell death, mCK may facilitate con-
tact between VDAC and ANT to form the pore at the contact site 
between the IMM and the OMM (Muravchick and Levy, 2006).
Interestingly, recent studies have provided evidence that exclude 
the ANT and VDAC as components of the mPTP. For example, 
genetic knockout studies showed that mPTP opening could occur in 
the absence of VDAC and ANT; nevertheless, they could both play 
a regulatory role. VDAC plays a critical role in the maintenance of 
mitochondrial function, and ultimately preserves cellular function, 
while ANT appears to function as a Pi and Ca2+ sensitive mPTP 
regulator. IPC protection could be mediated by the phosphoryla-
tion and inhibition of GSK-3β, a downstream target of Akt, thereby, 
inhibiting mPTP opening in part by binding to ANT (Nishihara 
et al., 2007). CypD was first identified as ANT-binding protein that 
mediated the inhibitory effect of cyclosporin A (CsA) on mPTP. 
The role of CypD in the regulation of cell survival or death is evi-
denced by the finding that cells lacking the Ppif gene that encodes 
the protein are protected from necrotic caspase-independent cell 
death, but not from caspase-dependent apoptosis (Kim et al., 2003; 
Baines et al., 2005; Basso et al., 2005).
Figure 3 | Simplified schema of changes in cytosolic and mitochondrial 
function during cardiac i/r injury and site of mitochondrial-targeted 
therapies with potential to reduce mitochondrial and cell damage. Targets 
are (a) the outer mitochondrial membrane (OMN), (e.g., putative mPTP 
components VDAC, ANT, etc.); (b) the inner mitochondrial membrane (IMM), 
[e.g., ANT, Ca2+ uniporter (CaU), Na+/Ca2+ exchanger (NCE), Ca2+/H+ exchanger 
(CHE)]; (c) the membrane potential (∆Ψm); (d) electron transport (complexes I–V); 
and (e) ATP synthesis/hydrolysis (complex V). Abbreviations: ETC, electron 
transport chain; SLP , substrate level phosphorylation; ROS, reactive oxygen 
species; RNS, reactive nitrogen species; mPTP , membrane permeability 
transition pore; ANT, adenine nucleotide translocator; VDAC, voltage dependent 
anion channel. Compounds: VAs, volatile anesthetics; CDZ, chlorodiazepine; HK, 
hexokinase; CGP , CGP37175: DNP , dinitrophenol; MnTBAP , Mn(II)tetrakis(4-
benzoate) porphyrin chlorine; CsA, cyclosporin A; NIM811, N-methyl-4-
isoleucine-cyclosporin; SS, Sezto–Schiller tetrapeptides; SFA, sanglifehrin; LRT, 
lipid replacement therapy; CCCP , carbonyl cyanide p-(trifluoromethoxy) 
phenylhydrazine, MnTMPyP , Mn(III)tetrakis[(1-methyl-4-pyridyl)-porphyrin]; IF1, 
inhibitory factor 1; CO, carbon monoxide; NIRL, near infrared light.
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recovery and more normalized mitochondrial bioenergetics in the 
isolated beating heart (Aldakkak et al., 2009).
Indeed, the targeting of mitochondrial ETC complexes to achieve 
cardioprotection has become an attractive approach compared to 
other remedies for protection against cardiac injury. For example, 
amobarbital and volatile anesthetics attenuate complex I activity, 
diazoxide reduces complex II activity, and hydrogen sulfide attenu-
ates complex IV activity (discussed below and shown in Figure 3). 
Because of the abundance of mitochondria in cardiomyocytes, these 
mitochondria represent a major source of O2
− (discussed below); 
on the other hand, mitochondria are also major targets of ROS. 
Therefore the successful targeting of mitochondrial complexes for 
a therapeutic purpose is in part ascribed to the vulnerability of the 
complexes and cardiolipin to oxidative stress (Paradies et al., 1997; 
Lesnefsky et al., 2001).
A defect in several of the respiratory complexes can be con-
sidered a potential source or inducer of O2
− during I/R. Paradies 
et al. (2004, 2009) reported that a decrease in complex I activity, 
as observed in I/R hearts, was associated with a decrease in state 3 
respiration. Others have coined the name “complex I syndrome” in 
which complex I inactivation is associated with protein nitration 
and oxidative damage to mitochondrial proteins and phospholi-
pids (Navarro and Boveris, 2009). On the other hand, a limita-
tion of e− transfer during ischemia to complex III, a major source 
of O2
−, represents a new concept to limit mitochondrial damage 
specifically during I/R (Lesnefsky et al., 2001; Chen et al., 2006, 
2008; Aldakkak et al., 2008a). In fact, we observed that attenuating 
complex I activity (e− flux) with the reversible inhibitor amobarbi-
tal protected the heart, and mitochondria in particular, from I/R 
injury when the drug was present only during ischemia (Aldakkak 
et al., 2008a). A recent study by Chen et al. (2010) showed that 
amobarbital given before ischemia preserved mitochondrial res-
piration in isolated mitochondria with glutamate and TMPD-
ascorbate, whereas sodium azide inhibition was not protective. 
The authors inferred that a specific region in the ETC, most likely 
between complex III and IV, leads to mitochondrial damage during 
ischemia (Chen et al., 2010). Although the Qo site of complex III 
is implicated in most of the ROS during I/R, Chen et al. (2010) 
postulated that the protection by antimycin A against I/R injury 
indicates that the specific site that elicits mitochondrial damage 
during ischemia is likely located in the segment between complex 
III and complex IV.
Other strategies for targeting the mitochondrial complexes have 
potential to be worthwhile approaches. For example, Hanley et al. 
(Hanley et al., 2002, 2003; Hanley and Daut, 2005) reported that 
the putative mitoKATP channel opener diazoxide may protect against 
I/R injury in part by inhibiting complex II, which could lead to less 
e− transfer to complex III and decrease reverse e− flow to complex I, 
and in the process minimize O2
− generation. In contrast, Wojtovich 
and Brookes (2009) reported recently that atpenin, believed to be 
a specific complex II inhibitor, increased post-ischemic recovery 
and decreased infarct size in a mitoKATP (blocked by 5-hydrox-
ydecanoate) channel sensitive manner. The authors observed that 
although atpenin interacts with complex II, it had no direct effect to 
decrease complex II activity and that it is indeed a potent mitoKATP 
channel activator (Wojtovich and Brookes, 2009). Thus, the benefit 
secondary to resisting Ca2+ overload (Zhang et al., 2008). Similarly, 
the derivative of CsA, NIM811, and the non-immunosuppressive 
sanglifehrin (SFA) inhibited mPTP opening (Theruvath et al., 
2008; Figure 3) and prevented cytochrome c release. In this way 
it is thought that normal e− transfer to complex IV (see below) 
and the scavenging potential of cytochrome c (discussed below) is 
also preserved. A clinical trial reported that targeting mPTP with 
post-conditioning or CsA at the moment of angioplasty improved 
contractile function and reduced cell death in patients with acute 
myocardial infarction (Ruiz-Meana et al., 2010). These studies do 
provide some encouragement for a clinical approach to delay or 
prevent irreversible mPTP opening. It is obvious that our under-
standing of the structural components and activity of the pore are 
crucial in our attempts to pharmacologically target the pore as 
a potential site for therapy (Figure 3). It is thus noteworthy that 
achieving control of the mPTP during the disease process is an 
important goal from the perspective of minimizing the early loss 
of functional and structural integrity, and for maximizing salvage 
following the initial injury.
theraPeutIc PotentIal of InterferIng wIth electron 
transPort chaIn and oxIdatIve PhosPhorylatIon
The IMM contains enzyme complexes and transport systems that 
are important in the transduction of energy from substrates that 
provide for the normal functioning of the cell. Under aerobic 
conditions, the ETC complexes allow proton translocation, and in 
the process, function to convey e− along and down a redox poten-
tial (Stowe and Camara, 2009; Lenaz and Genova, 2010; Lenaz 
et al., 2010). Electrons are transferred from NADH and FADH2 
from complex I and II, respectively, to downstream redox centers 
(Figure 1). The complexes are thought to be dispersed randomly in 
large groupings called respirasomes or supercomplexes, which are 
held in place by cardiolipin and which are functionally connected 
to coenzyme Q and cytochrome c (Stowe and Camara, 2009; Lenaz 
and Genova, 2010; Lenaz et al., 2010). The supercomplex is thought 
to improve the efficiency of OxPhos by eliminating the diffusion of 
substrates and products between individual complexes (Paradies 
et al., 2009). The ubiquinone moiety is redox active, accepting two 
e− and two H+ in its reduction to ubiquinol (James et al., 2005). 
Concomitant to the e− transport, H+ ions are pumped from the 
matrix into the IMS (Figure 1). The energy released during the 
process is efficiently utilized to phosphorylate ADP to ATP by trans-
location of H+ from the IMS to the matrix through complex V (F1/
F0 ATP synthase; Stowe and Camara, 2009; Camara et al., 2010b). 
Hence OxPhos results in transient dissipation of ∆Ψm.
Cardiomyocytes, like neurons, depend almost entirely on 
OxPhos for their function. Therefore, structural preservation of 
the ETC complexes/supercomplexes is paramount in maintaining 
a high bioenergetic status to provide efficient cellular homeostasis 
with minimal ROS production (Camara et al., 2010b). In fact, mito-
chondrial defects encompassing complex I–IV of the ETC likely 
characterize a large number of human diseases (Cohen and Kesler, 
1999a,b), at least in part. In a recent preliminary study, we reported 
that cardiac I/R disrupted the supercomplex structures and that 
ranolazine, a late Na+ channel blocker and an anti-anginal drug, 
preserved the integrity of the complexes following I/R (Gadicherla 
et al., 2010). This preservation of the mitochondrial supercomplexes 
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it provides an alternative approach to cardioprotection against I/R 
injury (Chen et al., 2007; Nadtochiy et al., 2007).
The structural integrity of the IMM is equally important in 
maintaining mitochondrial function to achieve normal and efficient 
OxPhos. As noted above, cardiolipin, a lipid high in unsaturated 
fatty acids content, is highly susceptible to oxidative and nitrosative 
stress (Armstrong, 2008). The loss of ETC complex activities has 
been ascribed to degradation of cardiolipin. For example, cardi-
olipin dysfunction can lead to impaired complex V activity, which 
would lead to impaired ATP levels, to a derangement of cellular 
ion homeostasis, and eventually to cell death. In a brain anoxia and 
reoxygenation model, mitochondrial lipid   peroxidation, cardioli-
pin damage and cytochrome c release, and collapse of ∆Ψm, were 
observed in isolated mitochondria, independent of mPTP opening 
(Morin et al., 2003b). Thus therapeutic targeting of cardiolipin 
is a reasonable alternative approach. Indeed, lipid replacement 
therapy (LRT) has gained significant traction recently as a thera-
peutic approach to restore mitochondrial membrane integrity and 
function as a means to mitigate oxidative damage (Figure 3). LRT 
involves actual replacement of damaged lipids of cellular and mito-
chondrial membranes. Fusion of mitochondria from I/R hearts, 
which contain lower levels of cardiolipin, with liposomes contain-
ing cardiolipin restored cardiolipin levels and preserved complex 
activities (Paradies et al., 2009). The restoration or preservation of 
the integrity of the IMM, specifically its cardiolipin content, is likely 
to be beneficial in restoring cardiac function. Overall, these studies 
highlight an emerging paradigm that restoration of mitochondrial 
structural integrity may improve ETC efficiency and hinder activa-
tion of apoptotic mechanisms.
As alluded to before, mitochondrial electrophysiology is crucial 
in determining whether there is mitochondrial function or dys-
function. An increase in K+ flux via the putative mitoKATP chan-
nel may lead to an increase in matrix volume and may result in 
more efficient ATP synthesis (Garlid et al., 2003) and better cellular 
preservation. In a recent study (Stowe et al., 2006) we provided 
novel evidence for a regulatory role of the putative mitoKCa on 
mitochondrial function and its cardioprotective value against I/R 
injury. Mitochondrial ROS scavengers abolished the cardioprotec-
tion implying a key role of ROS in activation of the putative mitoKCa 
channel-mediated cardioprotection. Putative activation of mitoKATP 
channels, for example with diazoxide, which as noted above has 
other effects on mitochondria, also has cardioprotective effects; 
preventing mCa2+ overload and subsequently preserving ∆Ψm are 
considered as possible mechanisms (Teshima et al., 2003a). The 
implications for the involvement of mitochondrial channels and/
or exchangers in cellular damage portend a potential therapeutic 
utility in the management of ischemic disease states.
theraPeutIc PotentIal of uncouPlIng ProteIns
Uncoupling proteins (UCPs), which are integral membrane pro-
teins located in the IMM (Figure 1), are important physiological 
regulators of mitochondrial function and redox potential; thus 
UCPs are also regulators of O2
− production. Uncoupled OxPhos 
results from e− transfer and H+ influx into the matrix independent 
of ADP phosphorylation (Sack, 2006b). UCPs stimulate mitochon-
drial respiration by partially dissipating the H+ gradient across the 
IMM, which tends to destabilize ∆Ψm. Excessive ROS accumulation 
commonly occurs in state 4 respiration due to the high electro-
chemical gradient and limited e− transfer. One of the effects of 
UCPs is to prevent buildup of ROS by partially dissipating the 
∆Ψm (Teshima et al., 2003a; Sack, 2006b). The physiologic role of 
uncoupled respiration is best exemplified by the adaptive thermo-
genesis induced by UCPs in brown fat. Because UCPs are capable 
of reducing mitochondrial ROS formation by modulating ∆Ψm 
(Haines et al., 2010), they have an impact to reduce the damaging 
effects of ROS during cardiac I/R or hypoxia injury (Fiskum et al., 
2004; Barreiro et al., 2009).
There are four UCPs variants (1–4) believed to induce inward 
H+ leak in energized mitochondria (Jezek et al., 1998; Stuart et al., 
2001; Brookes, 2005; Stowe and Camara, 2009) (Figure 1) and 
thereby to uncouple OxPhos. This uncoupling is well established 
for UCP1 with its central role in thermogenesis whereas the func-
tions of the other isoforms are still being debated. UCP2 and UCP3 
are present in the heart and provide some cardioprotection (Sack, 
2006b). Knocking out UCP2 increased brain damage after middle 
cerebral artery occlusion (Haines et al., 2010). Other studies show 
that UCP2 overexpression is inversely correlated with caspase-3 
activation in neurons (Deierborg et al., 2008). In rat neonatal 
cardiomyocytes, UCP2 overexpression confers tolerance to oxida-
tive stress via diminished mCa2+ uptake and reduced ROS pro-
duction (Sack, 2006b). Some lipid peroxidation products, such as 
4-hydroxy-trans-2-noneal (HNE), may induce partial uncoupling 
of mitochondria through UCPs and are thereby also reported to ini-
tiate protective mechanisms (Boss et al., 1997; Echtay et al., 2003).
It is worth repeating that during myocardial I/R injury or heart 
failure an increase in catecholamine concentration activates FA 
utilization in cardiomyocytes by β-oxidation. With increased 
β-oxidation there is a concomitant increase in mitochondrial 
ROS, but gene expression of UCPs is also activated so that tends 
to reduce ∆Ψm and ROS production. So it is interesting that chronic 
treatment with trimetazidine, which partially blocks β-oxidation 
in the matrix, has been shown to mitigate ischemic or heart failure 
disease (Ashrafian et al., 2007), but this may be counterintuitive 
as β-oxidation furnishes more energy per carbon than glycolysis.
In a recent study we (Heinen et al., 2007) suggested that a small 
H+ leak brought on by the putative mitoKCa channel opening NS1619 
in cardiomyocytes led to ROS production without substantially 
changing ∆Ψm. It is possible that this “mild” uncoupling may con-
tribute to the protection of the heart against I/R injury as shown by 
NS1619 (Stowe et al., 2006). We showed that the NS1619-induced 
protection in isolated hearts was mediated by preservation of mito-
chondrial redox state, reduced mCa2+ loading, decreased deleterious 
ROS production, and better functional recovery; this protection 
was abolished when hearts were treated either with MnTBAP, an 
antioxidant, or paxilline, a KCa channel antagonist (Camara et al., 
2010b). It has also been suggested that mitoKATP channel openers 
(Murata et al., 2001) and volatile anesthetics (Sedlic et al., 2010a,b) 
are cardioprotective by virtue of inducing a “small amount” of 
ROS production and mild uncoupling of mitochondria (Figure 3).
In addition to stimulating UCPs to ameliorate pathological ROS 
production and protect against oxidative injury, there is the poten-
tial therapeutic use of low doses of artificial uncouplers to target the 
mitochondrion. One such drug is the protonophore dinitrophenol 
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PotentIal theraPIes
In this and the subsequent section, ROS (O2
−, H2O2 and OH
, etc.) 
and RNS (NO
 and ONOO−, etc.) generation and scavenging will 
be discussed. Under the physiologic state, “small amounts” of 
O2
−  are formed during mitochondrial respiration, but which are 
maintained at acceptable levels by endogenous matrix antioxidant 
defenses (Tsutsui et al., 2006) (Figure 4). A “small amount” of ROS 
is important in normal cellular function. In excitable tissue, espe-
cially cardiac and neuronal, mitochondria represent a major source 
of  O2
−  as a consequence of large mitochondrial numbers and a 
high level of OxPhos (Cadenas et al., 1977; Cadenas and Davies, 
2000; Andreyev et al., 2005). H2O2, a relatively inactive compound, is 
generated from dismutation of O2
−, and in a Fe-dependent Fenton 
(DNP), which has been utilized to treat obesity (Camara et al., 2010b). 
However DNP, if used in excess can markedly reduce ∆Ψm, so its 
low therapeutic index limits its utility as a viable therapeutic option 
(Blaikie et al., 2006). Similarly, low concentrations of carbonyl cyanide 
p-(trifluoromethoxy) phenylhydrazine have been reported to pro-
tect by preventing mPTP opening (Teshima et al., 2003b) (Figure 3). 
Taken together, these findings suggest that a better knowledge of the 
ionic mechanism of H+ leak by UCPs and synthetic uncouplers could 
provide the basis for better design of mitochondriotropic drugs to 
reduce cellular injury following oxidative stress. Indeed, animal stud-
ies of heart failure and transgenic mouse models have suggested that 
UCPs may be important in the endogenous response of heart muscles 
to oxidant stress and that UCPs may be a potential target for heart 
disease therapy (Laskowski and Russell, 2008).
Figure 4 | Principal mechanisms for mitochondrial reactive oxygen species 
(rOS) generation. Reduced substrates synthesized in metabolic pathways 
supply e− to complex I and complex II of the ETC. The major centers for 
superoxide (O2
−) formation are complex I and complex III, although small amounts 
may also be formed at complex II and complex IV (omitted for clarity). The 
electron carrier of complex III ubiquinone (Q) is reduced to ubiquinol (QH2), which 
transfers an electron to cytochrome c (Cy C) through a Fe protein (not shown) 
inhibited by myxothiazol (Myx). The resulting semiubiquinone (Q•) is oxidized back 
to ubiquinone by cytochrome b (Cy b), and can also transfer e− to O2 to form O2
−. . 
Myx reduces O2
− production because it blocks Q• formation, whereas antimycin A 
(Ant A) enhances it by increasing Q• levels. The drug rotenone (Rot) inhibits 
electron flow distal to O2 generation, enhancing its production. The O2
− generated 
by Myx and Ant A are topographically oriented, whereas the O2
− generated by 
Myx are directed to the matrix where they are scavenged; O2
− generated by Ant 
A are released into the IMS and so escape the powerful matrix scavengers. The 
figure also depicts the dismutation of ROS and the reaction O2
− and NO
 to 
generate ONOO−. A better understanding of the topographical sites of O2
− 
generation and the role it would have in a disease process could be important in 
targeted scavenging of ROS to mitigate or prevent the initiation or progression of 
a particular-mitochondria-related dysfunction and cardiovascular abnormalities. 
Modified reproduction with permission (Camello-Almaraz et al., 2006). SOD, 
superoxide dismutase; H2O2, hydrogen peroxide; ONOO−, peroxynitrite; NO
, 
nitric oxide; ∆Ψm: mitochondrial potential; AS, ATP synthase; OMM, outer 
mitochondrial membrane; IMM, inner mitochondrial membrane; GSH and GSSG 
reduced and oxidized glutathione, respectively; GPX, GR and CAT glutathione 
peroxidase, glutathione reductase and catalase, respectively.
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 that is released from the vascular 
  endothelium probably exerts an important role in regulating 
mitochondrial respiration. NO
 and its derivatives have emerged 
as significant players in the control of mitochondrial function and 
dysfunction (Camara et al., 2010b). Some of the effects of RNS 
include: (1) competitive inhibition of cytochrome oxidase (com-
plex IV), (2) partial inactivation of complex I, (3) activation of 
mPTP, and (4) stimulation of mitochondrial biogenesis (Camara 
et al., 2010a).
The inhibition of complex I by S-nitrosation has surfaced 
recently as an important mechanism in cardioprotection by IPC 
due to the direct action of NO
 on mitochondria independent of its 
effects on the soluble guanylate cyclase signaling pathway (Burwell 
et al., 2009). In a way, the partial inhibitory effect of NO
 on complex 
I is analogous to the protective effect afforded by amobarbital on 
complex I (Aldakkak et al., 2008a). However, the effect of NO
 
to bind to complex I can also result in increased O2
− and H2O2 
(Camara et al., 2010a). Furthermore, NO
 reacts with O2
−  to gen-
erate the potent RNS product peroxynitrite (ONOO−; Figure 4).
The main source of NO
  in cardiac mitochondria likely arises 
from the vascular endothelium, but there are other potential 
cytosolic sources, such as nerve terminals or mitochondria.  NO
 
has multiple targets in mitochondria including metalloproteins 
containing Fe–S clusters that are known to be highly sensitive to 
a direct oxidative modification by NO
; other important targets 
are the lipid thiols. Like O2
−  the role of NO
 and its products in 
the cell is akin to a “double-edged” sword. NO
 can act both as 
a vasodilatory and cardioprotective molecule and as a facilitator 
of cellular injury. NO
 can act directly on mitochondria, inde-
pendent of guanylate cyclase, to protect tissue/organs, or it can 
provide protection by way of a NO
-mediated signaling cascade. 
But, the most important feature of NO
 in mitochondria is likely 
the competitive, reversible inhibition of O2 binding at complex IV. 
The NO
 inhibition of O2 binding is reversible as this depends on 
the concentration of the two gases in the mitochondrion (Camara 
et al., 2010b).
Although there is considerable support for the concept that 
NO
 per se is cardioprotective, the exact mechanisms for this effect 
remains to be unraveled. Under physiological conditions, when the 
O2 concentration is low, NO
 may effectively act as a regulator of 
the mitochondrial ETC to induce reversible inhibition of e− trans-
fer. In this situation, NO
 generation during hypoxia may lower 
mitochondrial respiration as an adaptation to lower O2 availability 
(Harrois et al., 2009). In addition, inhibition of complex IV by 
NO
 is thought to elicit cardioprotection by preserving the limited 
supply of O2. NO
,  in limited amounts, may also provide protec-
tion against I/R injury in part by preserving cardiolipin (discussed 
above under IMM), which is essential for complex IV function, 
and to minimize cytochrome c release and other apoptotic factors 
(Gorbunov et al., 1997; Osipov et al., 2006; Vlasova et al., 2006). Of 
course, nitration of amino acid residues in the ETC complexes and 
other proteins (VDAC, ANT), likely leads to altered enzyme func-
tion. Nitrosation of complex I on the other hand, has been shown 
to protect against I/R injury (Nadtochiy et al., 2007). In a recent 
study, Cheng et al. (2011) reported that NO
 caused a concen-
tration-dependent biphasic inhibitory effect of the cardiac VDAC 
that was incorporated into a planer lipid bilayer. The   implications 
reaction, it generates the toxic radical group Fe=O• (Stowe and 
Camara, 2009). When administered on reperfusion the Fe chelator 
desferrioxamine was found to improve function during cardiac I/R 
(Lesnefsky et al., 1990; Dobsak et al., 2002; Liachenko et al., 2003).
Many more recent observations indicate that the targeting of 
mitochondrial O2
− as a therapeutic goal in cellular dysfunction 
requires a careful balancing of the “good” (physiological) and “bad” 
(pathological) O2
−. Small amounts of ROS have been implicated 
in pre- and post-conditioning cytoprotection as evidenced by the 
loss of protection in the presence of scavengers (Stowe and Camara, 
2009; Camara et al., 2010b). When ROS production exceeds the 
capacity of detoxification and repair pathways, oxidative damage 
to proteins, DNA (mtDNA and nDNA), and membrane lipids such 
as cardiolipin occurs. In post-mitotic cells the continuous accu-
mulation of oxidative damage triggers the accumulation of non-
functional mitochondria, a process that could lead to mitochondrial 
autophagy. These conditions can culminate in impaired ATP gen-
eration and cell death (James et al., 2005). Hence, mitochondrial 
ROS generation and oxidative damage are potential targets (Figure 
3) to apply pharmacological and molecular approaches for thera-
peutic interventions (James et al., 2005) as discussed in detail below.
Although O2
− is generated from several sources in the mitochon-
drion, the main source of mitochondrial O2
−  appears to be within 
the IMM of the ETC, in particular at complexes I and III (Turrens 
and Boveris, 1980; Cadenas and Davies, 2000; Chen et al., 2003, 
2007). However, the specific sites and mechanisms of O2
−  genera-
tion remain unsettled (Turrens et al., 1985; Ambrosio et al., 1993; 
Babcock and Varotsis, 1993; Chen et al., 2003). In intact mitochon-
dria from normal hearts, ROS are formed from complex I when 
e− flux is backward from complex II, or at the ubisemiquinone site 
of complex III (Camara et al., 2010b), where a radical intermediate 
is formed through the Q-cycle of the complex, particularly at the 
Qo site (Figure 4). Indeed experiments have shown that complex 
III generates O2
− through the oxidation of ubisemiquinone, which 
faces the IMS, while complex I mediated O2
− generation is directed 
mostly toward the strongly scavenging matrix side (Chen et al., 
2003, 2007, 2008).
In cardiac I/R injury, impaired complex I can enhance O2
−  
generation as a result of increased e− leak as e− transfer is impeded 
(Camara et al., 2010b). When FADH2 related substrates are used 
and an e− enters the ETC at complex II, O2
− may be generated by 
reverse e− transfer to the FMN site of complex I (Chen et al., 2007; 
Zoccarato et al., 2007; Stowe and Camara, 2009). Although complex 
I is a site for O2
− generation (Chen et al., 2008), complex III may 
become a major site for O2
− generation (Chen et al., 2008) in cardiac 
cells under ischemic conditions. Ischemia damages complex III by 
functionally altering the Fe–S protein subunits (Chen et al., 2007). 




− -scavenging) under pathological conditions can also occur 
as a consequence of depletion or a defect in the mitochondrial 
antioxidant system (Camara et al., 2010b). The increase in ROS 
production can contribute to a self-regenerating ROS production 
facilitated by ROS-induced ROS release (Zorov et al., 2000; Brady 
et al., 2006b; Stowe and Camara, 2009). This increase in oxidative 
stress will result in further damage to mitochondria. A point is 
reached where the scavenging system almost completely collapses 
and emission of ROS is further perpetuated in a vicious cycle.
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ONOO− has also been reported to be cardioprotective (Nossuli 
et al., 1998).
Low levels of ONOO−, however, may actually provide protec-
tion (Camara et al., 2010b) through its decomposition products, 
NO2 and NO3 (Szabo et al., 2007), by reacting with glutathione 
to form S-nitrosoglutathione (Nossuli et al., 1998), and/or by 
acting as an intermediate in preconditioning (Ferdinandy and 
Schulz, 2003). The earliest evidence in favor of a protective effect 
of ONOO− is its decomposition to other nitrogen compounds by 
the Fe(III) porphyrin compounds in the carrageenan-induced paw 
edema model (Szabo et al., 2007). Since then, other studies have 
reported ONOO− furnishes protection against diabetes-associated 
impairment of erectile dysfunction and I/R injury. In I/R injury 
the cardioprotective effect were demonstrated by reduced infarct 
size and improved contractile function (Ronson et al., 1999; Szabo 
et al., 2007).
In cardiomyocytes, ONOO− protection may be mediated in part 
by nitration of PKCε, which in turn activates mitoKATP channels 
resulting in inhibition of mPTP opening. ONOO− conversion to 
NO
 in the presence of hemoglobin, or decomposition of nitrite 
in the presence of myoglobin nitrite reductase to form NO
, may 
all lead to protection by inhibiting complex IV or by activation 
of mitoKATP, to block mPTP opening (Gladwin and Kim-Shapiro, 
2008; Nediani et al., 2011). As noted above, NO
 can also inhibit 
the ETC thus tending to preserve O2 gradients during ischemia and 
to favor a more controlled resumption of respiration during reper-
fusion to minimize ROS production (Nediani et al., 2011). Clearly, 
the mechanism of protection by nitrogen containing molecules, 
such as nitrites, await further characterization, and the reproduc-
ibility of this effect in multiple animal models of I/R suggests nitrite 
as a novel potential therapy for ischemic heart diseases (Nediani 
et al., 2011).
PotentIal theraPeutIc value of MItochondrIal ros 
scavengIng
Under physiologic conditions, scavengers or antioxidants can 
attenuate the toxic effects of ROS and RNS. This is because mito-
chondria are endowed with an elaborate and well-defined multi-
leveled antioxidant defense system of enzymes and non-enzymes 
to quench mitochondrial O2
−. The scavenging system includes the 
matrix MnSOD and glutathione (GSH; Figure 4) and thioredoxin 
(TRXSH2) systems, cytochrome c, peroxidase, catalase, and others. 
A detailed review of ROS scavengers, which is beyond the scope 
of this review, has been discussed in recent comprehensive review 
articles by two of the authors (Stowe and Camara, 2009; Camara 
et al., 2010b).
The association of increased ROS generation in various patho-
logical conditions has made development of the ideal antioxidant 
therapy to target the mitochondrion an important goal (Camara 
et al., 2010b). Recent evidence suggests that targeting O2
− emis-
sion during I/R requires adoption of alternative approaches, i.e., 
focusing on the O2
−  generation that occurs during ischemia as well 
as the O2
−  emission during reperfusion (Camara et al., 2010b). 
O2
− generation during ischemia sets the stage for an increase in 
O2
− emission during reperfusion as a mechanism of cellular injury 
(Chen et al., 2007, 2008; Aldakkak et al., 2008a). As noted before, 
of these novel findings is that post-translational modification of 
VDAC by NO
 and other nitrogen containing molecules may be 
important in regulating the function of the channel, thereby pre-
serving mitochondrial function and cell survival. Lastly, NO
 is 
reported to decrease mCa2+ overload by binding to complex I and 
this appears to be associated with a decrease in ∆Ψm (Solaini and 
Harris, 2005; Burwell and Brookes, 2008).  NO
 is a mediator of 
preconditioning through several putative pathways (Camara et al., 
2010b). It is plausible that some of the protective effects of NO
 can 
also be attributed to a coordinated series of responses by modest 
levels of NO
,  which indirectly enhances mitochondrial function 
by increasing local blood supply to enhance O2 and substrate deliv-
ery to mitochondria (Camara et al., 2010b).
At higher concentrations, NO
 appears to shift the balance from 
cytoprotection toward damage and apoptosis. Increased mitochon-
drial  NO
  may induce cell death by necrosis and apoptosis via 
mPTP opening (Solaini and Harris, 2005). Indeed, as noted else-
where, ONOO− is thought to be an important mediator of tissue 
injury in myocardial ischemia-reperfusion (Camara et al., 2002). 
The most damaging effects of NO
 activity on mitochondria are 
attributed to an increased susceptibility of cardiolipin to ONOO− 
(Chen et al., 2007). It is important to note that while NO
 mainly 
reacts reversibly at complex IV, ONOO− is known to affect com-
plexes I, II, and V by irreversible nitration of the tyrosine residues 
(Duchen, 2004). Thus conditions leading to excess ONOO− will 
promote enhanced mitochondrial lipid/protein damage, Ca2+ 
uptake and swelling, rupture or increased permeabilization of 
OMM and cytochrome c release. ONOO− also can directly oxidize 
glutathione (GSH; (Harrois et al., 2009).
The balance between physiologically relevant levels and patho-
logical concentrations of NO
 is critical in the role of this gas 
in mitochondrial function (Kim et al., 1999) and points out the 
difficulty in maintaining a delicate balance between NO
 gen-
eration and ONOO− production during development of poten-
tial therapeutic approaches to target mitochondria. Given that 
ONOO− is an intermediate formed from NO
 and O2
−, inhibi-
tion of either O2
− or NO
 generation will attenuate the levels 
of ONOO− and minimize mitochondrial damage (Camara et al., 
2010b). For example, overexpression of MnSOD has been shown 
to protect neuronal-like cells against NO
-dependent cell injury, 
tyrosine nitration, and lipid peroxidation. In addition, overex-
pression of nNOS initiates NO
-dependent neuronal cell death, 
which is alleviated in cells enriched in MnSOD (Radi et al., 2001). 
However, the chemical reaction between NO
 and O2
−  is faster 
than the reaction with MnSOD (Ferdinandy and Schulz, 2003) 
and ONOO− mediated inactivation of the enzyme amplifies  NO
 
and ONOO−-dependent mitochondrial oxidative stress (Radi 
et al., 2001). It is reported that ONOO− can inhibit mitochon-
drial aconitase (Hausladen and Fridovich, 1994) and stimulate the 
release of AIF and other apoptogenic factors from mitochondria, 
which in turn leads to DNA fragmentation or increased cyto-
chrome c peroxidase activity that can worsen the oxidative damage 
of mitochondrial proteins and membranes (Szabo et al., 2007). 
Overall, a targeted approach against excess ONOO− and NO
  
with allowance for “small” concentrations of NO
 as a signaling 
mediator for cytoprotection may be an important initial strategy 
to protect against cardiac cell injury from oxidative/nitrosative 
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NADP), determine the cellular redox status. Oxidative stress and 
redox status are widely considered as major facets of mitochon-
dria-related diseases/abnormalities. In fact, one defense against 
I/R-induced ROS accumulation and damage may involve preser-
vation of the NAD(P)H pool (Camara et al., 2010b). An adequate 
NAD(P)H/NAD ratio, maintained through an NADH kinase and 
transhydrogenase (Hanukoglu and Rapoport, 1995; Outten and 
Culotta, 2003)-dependent mechanism, preserves the mitochondrial 
NAD(P)H pool required to maintain the redox status necessary 
for effective scavenging. Thus the redox homeostasis in mitochon-
dria is regulated by the coordinated activity of various antioxidant 
mechanisms including the GSH, thioredoxin (TRX; Camara et al., 
2010b), and other redox systems. Therefore, these thiol-reducing 
agents are critically involved in defense against large increases in 
O2
−  emission (Sen, 1998; Ueda et al., 1998; Lin and Beal, 2006; 
Stowe and Camara, 2009).
GSH is a small molecule with a thiol (-SH) residue of cysteine as 
its active site. Under conditions of oxidative stress, large amounts 
of GSH are rapidly oxidized to GSSG. The enzyme glutathione 
reductase (GR) uses NAD(P)H/NADH as its source of e− to regener-
ate GSH. Hence an increased concentration of NAD(P)H/NADH 
relative to NADP+/NAD+ promotes the production of GSH via GR 
(Figure 4). GSH protects mitochondria from extra-mitochondrial 
ROS and detoxifies O2
− in a non-enzymatic fashion. Mitochondria 
appear to be most susceptible to damage during a GSH-depleted 
state (Stowe and Camara, 2009; Camara et al., 2010b). Inhibition 
of GSH transport results in depletion of mitochondrial GSH and 
increased oxidative damage (Aon et al., 2007) and subsequent cel-
lular injury. In addition to protection against ROS, GSH is an ideal 
scavenger of HNE and other lipid peroxides (Calabrese et al., 2005).
Mitochondrial thioredoxin reductase-2 (TrxR-2) is present in 
large concentrations in the brain, heart, and liver (Rybnikova et al., 
2000). TRX is reduced by TrxR-2, which utilizes the mitochondrial 
NADH/NAD redox state similar to GR as a source of reducing 
equivalents. TRX protected against H2O2-induced cytotoxicity, 
improved post-ischemic ventricular recovery, and reduced infarct 
size when compared to hearts from wild type mice (Ebrahimian 
and Touyz, 2008; Ebrahimian et al., 2008). The TRX system has also 
been shown to have a potential therapeutic value against cardiac 
hypertrophy and cardiac failure (Stowe and Camara, 2009; Camara 
et al., 2010b).
The contribution to scavenging potential of mitochondria by 
these redox proteins is therefore dependent on normal mitochon-
drial bioenergetic function and the availability of reducing equiva-
lents. Thus, maintaining a large pool of reductants like GSH and 
TRX requires mitochondria to regenerate the reduced state via the 
NADH/NAD+ redox pair after detoxifying the ROS. Hence, supply-
ing exogenous GSH or TRX-2 may be protective, but only if there 
are also sufficient reducing equivalents.
Catalase is present in the cardiac cell mitochondrial matrix in 
extremely small amounts (Andreyev et al., 2005). Catalase pro-
tects mitochondria against intra- and extra-mitochondrial gener-
ated H2O2 (Andreyev et al., 2005). GPx, ubiquitously expressed 
in mammalian tissues and present in the mitochondrial matrix, 
seems to be the dominant H2O2 detoxifying agent in the heart. 
Catalase or GPx coupled to GR converts H2O2 to H2O (Fruehauf and 
blockade of complex I and III with amobarbital and antimycin A, 
respectively, can protect mitochondria against ischemic damage 
(Chen et al., 2010). Clinically, this is a relevant area of research 
because patients with active myocardial ischemia could theoreti-
cally receive pharmacologic therapies that target the spatial and 
temporal aspects of ROS production. Pharmaceutical agents that 
provide ROS scavenging systems are most effective if they address 
the problem at its source, in this case within the IMM (Hoye et al., 
2008). Overall, a better understanding of the sources and direc-
tion of O2
− generation from the mitochondrion is crucial to an 
understanding of the potential of particular antioxidants used to 
mitigate oxidative stress and cellular damage. However, effective 
delivery of these antioxidants into the cytosol or matrix as a therapy 
remains elusive and problematic. Attempts to address these physi-
cal limitations are being pursued by reformulations of different 
therapeutic antioxidants based on the much larger ∆Ψm than cell 
membrane potential.
Because MnSOD is located primarily in the matrix (Figure 4), it 
plays an essential role in protecting against oxidative stress, and is 
therefore a critical component of normal development and survival. 
Its only known function is to detoxify O2
− to H2O2. MnSOD is a 
nuclear-encoded protein that is transported to the mitochondria via 
a targeting sequence through the import machinery. A number of 
studies have shown better cell survival under oxidative stress, e.g., 
lipopolysaccharide treatment, by increasing the level of MnSOD 
(Czaja et al., 1994; Rogers et al., 2001). In SOD2+/− mice, brain 
infarct size is greater than wild type after focal cerebral ischemia. 
Accordingly, overexpression of MnSOD results in neuroprotection 
(Duckles et al., 2006).
Mitochondrial MnSOD mimetics (non-protein) have been 
developed to allow uptake into the mitochondrion to scavenge ROS. 
The mitochondrial superoxide dismutase mimetics MnTBAP and 
MnTE-2-Py5+ are permeable to the IMM and are capable of scav-
enging O2
− and ONOO− (Saba et al., 2007). MnTBAP was shown to 
improve survival in MnSOD knock out mice (Benov et al., 1998) and 
to decrease mitochondrial ROS production (Camara et al., 2004). 
Another cell-permeable MnSOD mimetic, Mn(III)tetrakis[(1-
methyl-4-pyridyl)-porphyrin] (MnTMPyP), has both MnSOD and 
catalase effects (Wang et al., 2004). Indeed, we observed that when 
MnTPyP was given before prolonged cold ischemia, it protected the 
isolated heart from ROS damage during I/R (Camara et al., 2007). 
The variant form of the porphyrin MnTE-2-Py5+, MnTnHex-2-Py5+, 
given 24 h before ischemia, preserved endogenous MnSOD and 
F0/F1 ATP synthase activities, with a concomitant increase in renal 
functional recovery. This action was unlike the classic MnSOD 
mimetics (Saba et al., 2007). However, it is unfortunate to note that 
attempts to incorporate these antioxidants in human cardiovascular 
preservation techniques remain either untested or are largely disap-
pointing (O’Connor and Gutterman, 2010). One would hope in 
time, and with rigorous testing and reformulations, the potential 
beneficial role of synthetic scavengers could lead to novel and useful 
mitochondriotropic antioxidants (Camara et al., 2010b).
In general, cellular antioxidant defenses depend on the reduc-
tion potential of the electron carriers and the reducing capacity 
of linked redox couples in the matrix [NADH/NAD+ and FADH2/
FAD] and cytoplasm (Stowe and Camara, 2009; Camara et al., 
2010b). The balance between oxidized and reduced species, i.e., 
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2004; Vendelin et al., 2005), have reported that fusion and fission 
are neither required for normal mitochondrial function in cardio-
myocytes, nor in all cell types. Consistent with these observations, 
Beraud et al. (2009) in an elaborate study, examined quantitatively 
the structural organization of mitochondrial dynamics and move-
ment in two different types of heart cells, i.e., adult cardiomyocytes 
and non-beating HL-1 (NB HL-1) cells, and reported that NB HL-1 
cells, but not the adult cardiomyocytes, showed fusion and fission. 
The dynamic fission and fusion in the NB HL-1 cells were observed 
only in dividing cells, which undergo rapid fusion–fission with 
formation of reticular networks. The observed differences between 
adult cardiomyocytes and NB HL-1 cells, according to the authors, 
are related to the specific structural organization of the cells, e.g., 
a variance in the mitochondria-cytoskeletal architecture (Beraud 
et al., 2009). From their findings, the authors (Beraud et al., 2009) 
contended that fusion and fission are demonstrated only in cultured 
cells of higher organisms or in yeast when these cells are actively 
dividing. They also argued that if mitochondria were fused in the 
cell, isolation of mitochondria should disrupt all mitochondrial 
membranes and release TCA cycle intermediates and render the 
mitochondrion unresponsive to TCA cycle linked susbtrates, e.g., 
pyruvate and glutamate (Beraud et al., 2009).
Nevertheless, fission and fusion have been implicated in a variety 
of biological processes, physiological, e.g., embryonic and neonatal 
development and metabolism, and pathological, e.g., I/R injury, 
heart failure, “diabetic” heart, vascular dysfunction, and apoptosis 
(Ong and Hausenloy, 2010; Williamson et al., 2010). Therefore, 
fusion and fission may be important in the etiology and/or propaga-
tion of mitochondrial dysfunction and ultimately cellular disorder, 
in some vascular cell types, such as endothelial cells. For example, 
fission might reduce propagation of mitochondrial ROS leading 
to less lipid peroxidation and loss of ∆Ψm, whereas fusion might 
facilitate spread of ROS and lead to mitochondrial destruction. 
Fission can also prevent cell death induced by Ca2+-dependent 
apoptotic stimuli that require mitochondria to amplify the lethal 
signals of this second messenger (Dorn and Scorrano, 2010). 
However, abnormal fission results in fragmented and bioenergeti-
cally impaired mitochondria. Fission also leads to destabilization 
of mitochondria while fusion may promote stable mitochondrial 
architecture and function. Yu et al. (2008) reported, for the first 
time, that maintenance of the tubular mitochondrial network by 
inhibiting mitochondrial fission in a sustained hyperglycemic con-
dition normalized cellular ROS levels and thwarted mPTP opening 
and subsequent cell death. Therefore, an understanding of this 
complex dynamic interaction between mitochondria, and between 
mitochondria and other organelles, is central to understanding 
the underlying causes of cellular dysfunction. It may also provide 
a potential for discovering novel therapeutic strategies for treating 
cardiovascular diseases (Ong and Hausenloy, 2010) using alterna-
tive protective mechanisms against oxidative stress.
Mitochondria can fuse with each other with the support of 
the cytoskeleton. Changes in the cytoskeletal architecture have 
recently been documented in patients with end-stage dilated and 
ischemic cardiomyopathies and, as such, may represent a common 
path for contractile dysfunction in the failing heart (Camara et al., 
2010a). Mitochondria are also capable of fragmenting into more 
Meyskens, 2007) to mitigate oxidative stress. Overexpression of 
GPx improves left ventricular pressure in mice after myocardial 
infarction (Laskowski and Russell, 2008). Recent studies have also 
shown that targeting catalase to the mitochondria can reduce car-
diac pathology (e.g., cardiomyopathy with age) consistent with the 
effect of accumulated endogenous ROS that may decrease heart 
functional capacity with aging (Treuting et al., 2008).
Lastly, cytochrome c, which is one of the mediators of apopto-
sis, can accept or donate an e− depending on the redox state of its 
heme (Fe). In this way it is also a scavenger of O2
− (Camara et al., 
2010b). The reduced cytochrome c is reinstituted by donating its 
e− to complex IV. In I/R injury, loss of cytochrome c through mPTP 
or OMM permeabilization, as a result of oxidative damage to cardi-
olipin and membrane proteins, inhibits or slows down respiration, 
which leads to increased e− leak (Zhao et al., 2003; Li et al., 2006); 
the outcome is a vicious cycle of more O2
− production and more cell 
damage. In the cytochrome c deficient Keilin–Hartree heart muscle 
model, Zhao et al. (2003) showed that e− transfer was impaired and 
O2
− generation was significantly greater in the mutant than in the 
wild type mouse. Reconstituting cytochrome c in the cytochrome 
c deficient hearts resulted in less O2
− accumulation. Therefore, an 
adequate concentration of cytochrome c in the ETC process is nec-
essary to maintain ROS at physiological levels (Zhao et al., 2003). 
Hence, maintaining the structural and functional integrity of the 
IMM and cytochrome c levels could represent a potential strategy 
for mitigating mitochondria dysfunction (Camara et al., 2010b) 
(Figure 3).
Thus it can be summarized here that under pathological condi-
tions a good understanding of the balance between the O2
−  produc-
ing side and its scavenging side is crucial for an effective therapy 
(Camara et al., 2010b). In ischemia the excess O2
−  appear to be 
confined to the production side and less to the detoxifying side. This 
is evident by the apparent intactness of the scavenging capability 
of GPx and MnSOD in isolated mitochondria during the ischemic 
insult (Starke et al., 1997; Jin et al., 2005). In the failing heart, 
on the other hand, increase ROS production is attributed in part 
to decreased expression of MnSOD and catalase (Laskowski and 
Russell, 2008). With these findings, the importance of decreasing 
oxidant stress in the ischemic and failing heart prior to reaching 
a critical mass that leads to irreparable damage is evident. Hence 
targeting the ETC to attenuate e− transfer and consequently to 
decrease the e− leak may represent a better strategy than attempt-
ing to change the matrix antioxidant capacity during ischemia 
(Camara et al., 2010b).
MaIntaInIng Intra-MItochondrIal and Intra-organellar 
InteractIons as a PotentIal theraPeutIc strategy
It is believed that in certain cell types, mitochondria are organ-
ized in a reticular system of interconnected organelles, whereas in 
cardiac cells they are thought to exist as individual units capable of 
undergoing dynamic fusion and fission (Dorn and Scorrano, 2010). 
These are processes that are regulated by fusion and fission proteins 
(Archer et al., 2008; Camara et al., 2010a), and they play a major 
role in regulating mitochondrial function and cellular metabolism. 
However, the occurrence of mitochondrial fusion and fission in 
the healthy adult heart is presently unclear, as these myocytes do 
not normally divide. Furthermore, Collins et al. (2002), Aon et al. 
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to the cell. For instance, mitochondria fission or failure of fusion 
appears to engage apoptotic mechanisms leading to cell degen-
eration (Duchen, 2004). Oxidative stress is one of the major trig-
gers of impaired mitochondrial dynamics. Substantial evidence 
indicates that mitochondrial fission occurs as a result of oxidative 
stress, which leads to loss of ∆Ψm and consequently to impaired 
mitochondrial function and increased cell vulnerability. For exam-
ple, acute exposure of myocytes to H2O2 leads to p53-dependent 
mitochondrial network fragmentation and the extent of the mito-
chondrial fragmentation (Li et al., 2010) correlates with a decrease 
in ∆Ψm (Camara et al., 2010b).
Indeed, in normal cells ∆Ψm is required for fusion. Specific 
fission and fusion proteins regulate this dynamic relationship by 
maintaining the IMM and by controlling cytochrome c release 
(Camara et al., 2010b). In cells derived from disease states, the 
compromise in ∆Ψm is a consequence of defects in ETC com-
plexes (McBride et al., 2006; Taguchi et al., 2007). This dynamic 
disintegration is observed in numerous mitochondrial associated 
cytopathies, including neurodegenerative diseases (Kwong et al., 
2007), pulmonary artery hypertension (Archer et al., 2008), and 
I/R injury (Aon et al., 2006a; Brady et al., 2006a). In pulmonary 
artery hypertension a decrease in mitofusin proteins contrib-
utes to disruption of mitochondrial fusion (Archer et al., 2008). 
Therefore, maintaining mitochondrial fusion by expression of 
fusion proteins, while minimizing the levels of fission proteins 
(Wang et al., 2009), could represent a novel therapeutic approach 
to improving cell survival during oxidative and nitrosative stress. 
In many diseases, in which a less polarized ∆Ψm may contribute 
to mitochondrial instability, a strategy to maintain integrity of 
the ETC with normal e− flux is a therapeutic option (Camara 
et al., 2010b).
Mitochondria also have anatomical and functional connectivity 
with other organelles such as the nucleus and the SR. These dynamic 
functional and structural interconnections are important for the 
normal coordination of cellular function. It is therefore anticipated 
that derangement of this dynamic link could be involved in patho-
logic states associated with cellular dysfunction. In some cell types, 
e.g., myocytes, mitochondria lie in very close apposition to the SR, 
and so are exposed to microdomains of high cytosolic [Ca2+] fol-
lowing local Ca2+ release from the SR. Evidence has emerged that 
there is a preferential coupling of Ca2+ transport from SR directly to 
mitochondria (Sharma et al., 2000), thereby providing a means for 
coupling cardiac muscle excitation to oxidative energy production, 
possibly through activation of Ca2+ sensitive mitochondrial dehy-
drogenases (Csordas et al., 2001; Hajnoczky and Csordas, 2010). 
Mitochondria–SR communication is therefore a crucial component 
in the normal function of mitochondria within the cell. The ana-
tomical proximity between mitochondria and ER conversely creates 
a local mitochondrial [ATP] within the microdomain required for 
SR Ca2+ regulation (Duchen, 2004; Szabadkai and Duchen, 2008; 
Figure 2). This dynamic relationship highlights the importance of 
Ca2+ signaling between the two compartments. For example, the 
low conductance form of the Ca2+-induced mPTP opening leads to 
Ca2+ extrusion from mitochondria; this may serve as an amplifica-
tion loop for Ca2+-induced Ca2+-release from the ER or SR stores 
(Pereira et al., 2009).
In the heart the inter-fibrillar mitochondria are closely inter-
twined with the SR to provide functional communication between 
the local ATP and the site for contraction (Dalen, 1989). Therefore, 
this proximity of mitochondria to Ca2+ release sites has functional 
consequences for intracellular Ca2+ signaling, capacitative Ca2+ 
influx, and cellular function (Duchen, 2004) and dysfunction 
(Camara et al., 2010b). Mitochondrial Ca2+ dynamics as well as 
emission of ROS are thus two key important events during the 
course of cellular injury and cell death. It has been proposed that 
these interactions are modulated in part by locally generated mito-
chondrial ROS, which is believed to act as the trigger to regulate 
the Ca2+ flux between the organelles (Waypa et al., 2002; Walsh 
et al., 2009) (Figure 2). A strategy of combined protection of mito-
chondria-SR dynamic anatomic and functional relationship may 
represent an innovative therapeutic approach to enhance organ 
viability (Du et al., 2008).
exaMPles of PotentIal theraPeutIc coMPounds to Protect 
MItochondrIal functIon
Given the marked importance of mitochondrial events during the 
initial critical phases of apoptosis, or in the propagation of many 
disease processes, the appropriate design of mitochondriotropic 
drugs is crucial in developing promising, novel strategies to mitigate 
cell injury and to prevent cell death. Because of the importance 
of this organelle in disease processes, either secondary or pri-
mary, a new field has emerged in the clinical realm that recognizes 
“Mitochondrial Medicine.” This is a new and rapidly developing 
medical research field. In recent years, the scope of the Society of 
Mitochondrial Medicine has expanded to pay increased attention 
to promote research and education for the diagnosis, treatment, 
and cure of mitochondrial disorders.
Mitochondria are ideal targets for therapeutic modification 
because they are key producers of ATP and ROS production, 
whereby an imbalance of the two factors can lead to apoptosis. As 
a first step in designing a mitochondria-specific therapy, it is fore-
most important to develop a drug that can access the matrix. One 
general solution is to utilize the large ∆Ψm and to attach a molecule, 
for example one with antioxidant properties, onto a lipoid vehicle 
that can penetrate membranes (Hoye et al., 2008). With a ∆Ψm of 
−180 mV under state 4 conditions, mitochondria-targeted drugs 
are preferentially taken up into the mitochondrion, with little or 
no accumulation in the cytosol (Camara et al., 2010b).
To achieve this goal, numerous approaches have been attempted. 
For example, the lipophilic agent TPP+, mentioned earlier, has been 
used to increase the incorporation of antioxidants and other thera-
peutic impermeants into mitochondria. The appended positively 
charged phosphonium moiety induces about a 1000-fold uptake of 
these compounds into the matrix over the cytoplasm. Indeed anti-
oxidants that accumulate within the matrix provide better protec-
tion from oxidative injury than untargeted antioxidants (Milagros 
Rocha and Victor, 2007). Examples include mitochondria-targeted 
ubiquinone (MitoQ), mitoTEMPO, and idebenone, currently 
under study for their possible use as therapies to decrease oxida-
tive damage in human pathological conditions (Maroz et al., 2009). 
These drugs accumulate in the mitochondria and could enhance 
ETC function, scavenge ROS, and prevent oxidation of cardioli-
pin, all of which may result in better functioning of   mitochondria 
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increases mitochondrial biogenesis and enhances O2
− detoxifica-
tion enzymes MnSOD and catalase (Das et al., 2010; Fulda et al., 
2010), all of which contribute to protection. At high concentra-
tions resveratrol has been shown to act as a pro-oxidant (Raval 
et al., 2008); it could also lead to inhibition of mitochondrial ATP 
synthesis by binding to F1-ATPase, or by triggering mPTP open-
ing, which would eventually contribute to cell injury. This suggests 
that the therapeutic role of resveratrol, as with other drugs, may be 
dependent on the concentration of the drug (Szende et al., 2000; 
Morin et al., 2003a).
There has recently emerged a novel class of cell-permeable anti-
oxidant peptides that are selectively partitioned into the mitochon-
drion independent of the ∆Ψm. These series of peptides, known as 
Szeto–Schiller (SS)-peptides can selectively target the IMM. For 
example, SS-31, which scavenges matrix H2O2 and ONOO−, reduced 
cytochrome c release and minimized mitochondrial swelling; its 
efficacy has been demonstrated in vivo by its effect to reduce cardiac 
and brain I/R injury in animal models (Cho et al., 2007; Thomas 
et al., 2007; Szeto, 2008a,b).
Other novel pharmacological agents may effect organ protec-
tion by optimizing substrate metabolism (discussed later) or by 
maintaining or improving oxidative capacity. However, it is clear 
that the subject of mitochondrial pharmacology is vast and the dis-
cussion presented here represents only a sampling of what has been 
uncovered to date. Nonetheless, the notion to use mitochondrial-
targeted therapeutics as an alternative approach is becoming an 
increasingly attractive strategy for treating cardiovascular diseases. 
One can predict that there will be whole classes of these so-called 
“mitochondriotropic drugs” under development in the near future.
PotentIal theraPeutIc IMPlIcatIons dIrected toward 
MItochondrIal ca2+ handlIng
Mitochondrial Ca2+ handling plays a key physiological and patho-
physiological role in the control of cellular function and dysfunc-
tion. Mitochondrial Ca2+ overload is a deleterious consequence 
of cardiac I/R injury and so mitochondrial Ca2+ handling is an 
important target for potential therapy (Camara et al., 2010b). As 
noted previously, the primary source of mCa2+ is external to the 
cell or from Ca2+ stored in the SR, following an increase in cytosolic 
Ca2+ uptake. Although modest increases in m[Ca2+] enhance enzy-
matic activity and subsequently OxPhos, massive mCa2+ loading 
can disable ATP synthesis. Under simulated or true I/R conditions 
the excess mCa2+ may contribute to mPTP opening and destabi-
lization of cellular ionic homeostasis, and eventually to cell death 
by necrosis or apoptosis. However, the targeting of mCa2+ dynam-
ics (uptake and release) for therapeutic purpose creates a difficult 
challenge that could impede the way forward in this area. These 
impediments include the structural identification of the CaU, NCE, 
NHE and a sodium-independent Ca2+ exchanger (NICE), and the 
myriad of other purported molecular structures that regulate the 
dynamic Ca2+ flux between the SR and mitochondria (see above).
Suffice it to say, however, that attempts have been being under-
taken to target mCa2+ in order to mitigate oxidative damage or 
I/R injury. Therapeutic approaches to reduce mCa2+ uptake lead-
ing to protection may involve direct targeting of the CaU or the 
mitochondrial exchangers that regulate m[Ca2+], or may involve 
(Schapira, 2006; Pope et al., 2008). CoQ10 is a natural antioxidant 
and a highly mobile e− carrier between complexes I and II to III. It 
is redox active and has been effective in reducing oxidative stress. 
It may provide some protection for patients with mitochondrial 
cardiomyopathies (Sokol and Treem, 1999).
Another mitochondrial-targeted antioxidant, the cationic 
SOD2 mimetic MnTBAP, can accumulate in cardiac mitochondria 
after systemic injection (Spasojevic et al., 2007). We showed that 
MnTBAP reversed the protection provided by the putative mitoKCa 
channel agonist NS 1619 (Stowe et al., 2006) and by IPC (Kevin 
et al., 2003). This demonstrates the fine line between scavenging 
harmful ROS and the ROS that are essential for signaling purposes. 
The mitochondrial-targeted scavenger mitoTEMPO decreased  O2
−  
and attenuated AII-induced hypertension, whereas when a similar 
dose of the non-targeted TEMPOL was given it was ineffective. The 
effect of mitoTEMPO was mimicked by overexpression of MnSOD 
(Dikalova et al., 2010). In an unrelated study, it was reported that 
SOD1 and mitoTEMPO prevented translocation of Bax to mito-
chondria and preserved mitochondrial integrity during simulated 
oxidative stress in tubular epithelial cells (Liang et al., 2010).
Metformin, an anti-diabetic drug also accumulates in the matrix 
of energized mitochondria due to its positive charge (Owen et al., 
2000). Metformin has a broad spectrum of effects that include fat 
breakdown and an increase in glucose transport and utilization 
(Zmijewski et al., 2008). Metformin has also been shown to protect 
against I/R injury (Calvert et al., 2008), possibly through the direct 
effects of the drug on complex I (Brunmair et al., 2004; Zmijewski 
et al., 2008), another action analogous to the action of amobarbital 
on mitochondria (Aldakkak et al., 2008a). Recent evidence suggests 
that metformin also can protect against oxidative stress. Metformin, 
via AMP-activated protein kinase, was reported to upregulate the 
expression/activity of thioredoxin, which, e.g., can attenuate the 
ROS generated by an enhanced FA load (Nediani et al., 2011). In 
the murine model of heart failure caused by I/R injury, metformin 
was effective in decreasing left ventricular dysfunction. This could 
make metformin a suitable mitochondria-directed therapy for pro-
tection against I/R injury and other cardiac vascular complications, 
particularly in the non-diabetic patient with heart failure (Nediani 
et al., 2011).
Another drug that also directly targets the mitochondrion is 
resveratrol (Sareen et al., 2006). Mitochondria represent a power-
ful target for resveratrol in the nervous system (Raval et al., 2008). 
Resveratrol is a polyphenolic compound derived from some grapes 
and roots; it is a natural antioxidant. It has been shown to reduce 
oxidative stress developed during reperfusion of the ischemic heart; 
it may also be in part effective against hypertension, cardiomy-
opathy, and heart failure (Das et al., 2010). Resveratrol has been 
shown to induce NO
 synthesis in the setting of ischemic reperfused 
heart, brain, and kidney, where it may lower the oxidative damage 
(Das et al., 2010). It has also been demonstrated that resveratrol 
can improve mitochondrial function and provide cardioprotection 
by stimulating the sirtuin 1 (SIRT1)-dependent deacetylation of 
the transcriptional co-activator peroxisome proliferator-activated 
receptor-γ co-activator 1α (PGC-1α) in a NAD+-dependent man-
ner. Because sirtuin depends on cellular NAD+ availability, mito-
chondrial regulation of NAD+ levels may contribute to an increase 
in sirtuin mediated PGC-1α deacetylation. Activation of PGC-1α 
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these pleiotropic/permeability issues will provide better insights 
into the role of CaU in cardioprotection.
SR stress results from a perturbation of SR homeostasis and 
has been implicated in cardiac contractile dysfunction associated 
with I/R and heart failure as a result of SR-induced intracellu-
lar [Ca2+] changes. Evidence suggests that IP3R-mediated release 
of Ca2+ from the SR appears to be a key-sensitizing step in vari-
ous apoptotic processes (Rizzuto et al., 2009). In early apoptosis, 
Ca2+ released from the SR activates mPTP; with the subsequent 
release of cytochrome c, this leads to an unrestrained increase in 
the local cytosolic [Ca2+] (Romagnoli et al., 2007). This might 
provide a direct mechanism for more matrix Ca2+ uptake. Ca2+ 
released via the IP3R is imported across the OMM through the 
VDAC (Rizzuto et al., 2009). Overexpression of VADC enhances 
mCa2+ uptake (Rizzuto et al., 2009) and this could offset the bal-
ance of mCa2+. All together, it is conceivable that interrupting the 
interaction between mitochondria and SR could mitigate (or pro-
mote) mitochondrial-mediated cellular damage. Thus targeting 
the dynamic Ca2+ flux within the microdomain, pharmacologically 
or by genetic manipulations, could provide potential therapeutic 
alternatives for reducing mCa2+ overload. Indeed, inhibition of SR 
Ca2+ release kinetics was proposed to reduce mCa2+ uptake and pre-
vent collapse of ∆Ψm or the release of cytochrome c (Rizzuto et al., 
2009). Akt phosphorylation of the receptor inhibits Ca2+ flux from 
the SR to mitochondria (Szado et al., 2008) and thereby inhibits 
apoptosis. Mao et al. (2008) in an elaborate study reported that the 
compound darbepoetin alfa, via activation of Akt, improved cardiac 
function and reduced cardiomyocyte apoptosis in a rabbit model 
of autoimmune cardiomyopathy. Therefore intrinsic activation of 
the Akt could be a potential therapeutic strategy in attenuating the 
transfer of Ca2+ during SR-mitochondrial stress and changes in Ca2+ 
levels within the microdomain. It has been suggested recently that 
mitochondria-SR crosstalk may play a greater role than previously 
suspected in cardiac hypertrophy and the progression to heart fail-
ure. It is possible that in heart failure therapeutic manipulations 
involving an increase sarcoplasmic reticulum Ca2+ ATPase (SERCA), 
or impaired function of its endogenous inhibitor phospholamban, 
could reduce the Ca2+ transient (Dorn and Scorrano, 2010) and 
reduce m[Ca2+] by which to improve OxPhos with adequate ATP 
production.
The mitochondrial K channels (ATP-sensitive or Ca2+ activated) 
have been shown to have potential cardioprotective roles. The open-
ing of mitoKATP or mitoKCa channels has been shown to be beneficial 
for cell survival under certain stress conditions, including I/R and 
heart failure (Ruiz-Meana et al., 2010). Opening of mitoKCa chan-
nels appear to protect hearts against infarction (Xu et al., 2002; 
Stowe et al., 2006) and similarly, activation of the mitoKATP has 
provided protection against I/R injury (Camara et al., 2010a). The 
precise mechanism for this protection has yet to be fully eluci-
dated. However, it is postulated that the opening of these channels 
produces both an increase in mitochondrial volume and a certain 
degree of uncoupling (mild depolarization) that reduces mCa2+ 
overload (Ruiz-Meana et al., 2010) and protects against apoptosis/
necrosis. We reported that activation of the mitoKCa channel with 
NS 1619 resulted in cardioprotection from I/R injury and that this 
was associated with reduced mCa2+ loading, better preservation 
indirect approaches that reduce Ca2+ release in the mitochondria-SR 
microdomain. For example, attenuation of mCa2+ overload and the 
subsequent reduction in the sensitivity of the mPTP opening has 
been attributed in part to inhibition of NHE or the CaU. Blocking 
NHE preserved ATP levels during cardiac I/R by improving state 
3 respiration (Javadov et al., 2008) and preventing mitochondrial 
Ca2+ overload (Camara et al., 2010b). In a recent study we also 
reported that activation or inhibition of NHE might act through 
mitochondria as shown by changes in redox state, ROS generation, 
and mCa2+ levels. We concluded from this study that the protection 
afforded by NHE inhibition may be due at least in part to inhibited 
mNHE, as well as sarcolemmal NHE. This notion is consistent 
with the observation that cariporide blocked matrix acidification 
and ATP depletion during simulated ischemia in cardiac myocytes 
(Ruiz-Meana et al., 2003). Under these conditions, one would 
expect a decrease in matrix pH with concomitant mitochondrial 
depolarization leading to diminished Ca2+ uptake.
The mNCE is another putative mitochondrial Ca2+ transporter, 
which is likely functionally similar to the sarcolemmal NCE, and 
it is sensitive to cations and a variety of pharmacological agents 
such as diltiazem and more specifically CGP37157 (Rizzuto et al., 
2009). Like the sarcolemmal NCE, the mNCE can operate in both 
directions depending on the trans-membrane cation concentra-
tions. During metabolic inhibition an increase in mCa2+ levels was 
observed despite a reduced ∆Ψm, which would limit uptake through 
the CaU (Hoppe, 2010). Indeed, it was reported that the rise in 
mCa2+ observed during metabolic inhibition was minimized by 
CGP37157. This mode of action may be particularly significant in 
diseased states with elevation of cytosolic Ca2+ and Na2+ levels dur-
ing heart failure (Hoppe, 2010). In addition, strategies to enhance 
extrusion of mCa2+ through the exchanger could lead to diminished 
mCa2+ load and reduce mitochondrial damage. This would make 
the targeting of mNCE a potential therapeutic target for mitigating 
Ca2+ overload during ischemia. However, direct targeting of these 
drugs to mitochondria with greater efficacy than on sarcolemmal 
exchangers remains elusive in so far as the molecular identity of 
the exchanger/transporters remains obscure.
The CaU, due to its close anatomical and physiological proxim-
ity to the SR RyR, is implicated in both normal cellular function 
and injury. Indeed, targeting the CaU in the local domain has been 
shown to mediate protection against I/R injury in various models. It 
has been shown to mediate IPC and to be directly involved in pro-
tection. Studies have shown that blocking the CaU with ruthenium 
red (RR) or RU360 prior to ischemia decreased the incidence of 
ventricular fibrillation (Brown and O’Rourke, 2010). We reported 
in preliminary studies that RR improved function and reduced 
mCa2+ load following I/R. Interestingly, we also observed in prelimi-
nary studies that RR significantly reduced the worsening of mCa2+ 
overload that was instituted by the perfusion of hearts with pH 8 
buffer (Aldakkak et al., 2008c), a condition that would maximally 
stimulate NHE and lead to increased cytosolic Ca2+ secondary to 
activation of NCE. However, as noted by Brown and O’Rourke 
(2010) in a recent review, it is difficult to draw conclusions on 
the effects of blocking the CaU due to the confounding effects of 
the ruthenium compounds on cellular Ca2+ fluxes, for example, 
blocking SR Ca2+ release. Even the more specific RU360 is trapped 
in controversy related to its membrane permeability. Until then, 
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gous to   mitochondrial associated myopathies with increased del-
eterious ROS production (Pipinos et al., 2006).
Under normal conditions, endothelial-derived NO
 may be able 
to modulate cardiac contractility, heart rate, coronary flow, and 
myocardial energetics. In pathological situations this role may be 
extended to regulation of cardiomyocyte metabolism and determi-
nation of cell survival. Unlike the cardiomyocyte, the endothelial 
cell is dependent more on glycolytic ATP production (cytosolic sub-
strate level phosphorylation) and less on mitochondrial OxPhos. 
Endothelial cells have far less mitochondrial density than cardio-
myocytes (5 vs. 40% cell volume, respectively). Consequently, mito-
chondrial ROS generation is likely much less than in myocytes. 
However, studies have indicated that vascular and endothelial cell 
mitochondria can represent a significant source of ROS, which 
in addition to cytosolic NAD(P)H oxidase (Nox) and xanthine 
oxidase-dependent ROS sources, contribute to the vicious cycle of 
ROS production and subsequent endothelial dysfunction (Dikalova 
et al., 2010). Increased vessel wall Nox-derived O2
− is indeed an 
important determinant of endothelial dysfunction in experimental 
angiotensin II (AII)-induced hypertension and genetic hyperten-
sion (Cave et al., 2006). Moreover, in a recent study, Dikalova et al. 
(2010) reported that endothelial cell mitochondria are the initial 
sources of ROS in response to AII-stimulated vascular dysfunction, 
whereas Nox is secondarily activated. This Nox-dependent ROS 
production could lead to a pathological process of mitochondria-
Nox axis in a feed-forward loop of deleterious ROS production 
(O’Connor and Gutterman, 2010).
It is evident that a loss of endothelial-derived NO
 bioavail-
ability is a critical component in the etiology of vascular dysfunc-
tion and is an independent risk marker for future cardiovascular 
complications.  O2
−  inactivation of NO
 by the uncoupling of 
NOS, contributes to vascular endothelial dysfunction. In addition 
to its indirect actions through inactivation of NO
,  O2
−  also likely 
exerts a direct action on vascular endothelium (Cave et al., 2006). 
Increased endothelial O2
−  and the concomitant production of 
ONOO− are likely to result in nitration of mitochondrial proteins 
that cause further damage to the organelle. It has been proposed 
that one of the major culprits in vessel damage is H2O2-mediated 
damage of the ETC (O’Connor and Gutterman, 2010), in which 
case reduction of H2O2 to H2O by antioxidants would help to amel-
iorate the damage. Damage to endothelial cell structure or function 
is considered to be among the primary causes of atherosclerosis 
(Davidson and Duchen, 2007) and other peripheral artery diseases 
(Pipinos et al., 2006). mPTP opening is prominent in endothelial 
cell-induced death leading to atherosclerotic lesions (Davidson and 
Duchen, 2007), so the mPTP is a potential target for minimizing the 
progression of atherosclerosis. In addition, endothelial cell mCa2+ 
overload, diminished levels of MnSOD activity, and decreases in 
ETC complex activities, have all been implicated in the events that 
lead to endothelial and vascular cell injury and death (Pipinos et al., 
2006; Davidson and Duchen, 2007).
A thorough understanding of the etiology of vascular dysfunc-
tion, specifically as it pertains to the role of mitochondria, may 
enable development of improved therapies for vascular diseases. 
Although treatment with antioxidants or with SOD mimetics has 
been effective in reducing oxidative stress and improving  endothelial 
of the redox state, and improved functional return (Stowe et al., 
2006). The activation of mitoKATP channels has also been proposed 
to mitigate mCa2+ loading as a mechanism of protection against 
I/R injury (Brown and O’Rourke, 2010).
Part 2
MItochondrIal dysfunctIon In endothelIal cells, heart 
faIlure, and I/r Injury
Given the fundamental function of mitochondria in cellular 
bioenergetics and oxidative stress, we have stressed that dysfunc-
tion within this organelle underlies the pathologic mechanisms 
of many diseases. In this section, a brief discussion of the role of 
mitochondria in vascular diseases, heart failure, and I/R injury will 
be presented. Potential therapeutic approaches that are targeted to 
mitochondria by which to mitigate cardiovascular damage also will 
be discussed. When mitochondrial ATP production is impaired 
tissues that rely heavily on high levels of ATP, such as the heart, 
skeletal muscle, and brain, are most affected. Depletion of ATP can 
lead, for example, to dissipation of intracellular ionic homeosta-
sis, cell swelling, and subsequent cell death by necrosis. In heart 
failure, defects have been purported to occur in ETC complexes 
or in components of the OxPhos machinery. These alterations 
are manifested frequently as cardiomyopathy (Rosca et al., 2008). 
Concomitant with impaired ETC function and OxPhos, increased 
O2
− generation and mCa2+ overload occur and lead to a “vicious 
perpetual cycle” of mitochondrial damage and dysfunction (Loeb 
et al., 2005); ultimately mitochondrial functional decline will lead 
to cell damage and organ failure.
Mitochondrial DNA is most susceptible to mutations because 
of its lack of histones and a limited repair mechanism. Increased 
oxidative stress leads to genetic mutations. Indeed, diseases related 
to mtDNA defects appear to be more prominent in brain and in 
skeletal and cardiac muscles where defects accumulate more exten-
sively than in rapidly dividing cells (Muravchick and Levy, 2006). 
It has been reported that in heart failure mtDNA damage leads to 
dysfunction and loss of mitochondrial mass (Murray et al., 2007). 
Mitochondrial related diseases have been discussed extensively in 
the literature (Duchen, 2004) and in our recent comprehensive 
review (Camara et al., 2010b).
treatMents targeted to endothelIal and vascular cell 
MItochondrIal dysfunctIon
Endothelial cells play a major role in vascular diseases and so their 
mitochondria are crucial in both the etiology and in the ameliora-
tion of the disease process. A primary role of the vasculature is in 
facilitating the delivery of O2 and energetic substrates for power-
ing the high metabolic demands of the cardiomyocytes; endothe-
lial cells are also critical in the development and manifestation 
of several types of cardiovascular disease that develop when the 
vasculature becomes damaged (Pipinos et al., 2006). Damage to 
endothelial cells can lead to atherosclerosis and to vascular com-
plications associated with diabetes and other peripheral artery dis-
eases. The manifestations of peripheral artery diseases are presumed 
to be due to reduced blood flow and vessel compliance. However, 
an increasing number of reports have implicated suboptimal bioen-
ergetic function from impaired endothelial cell mitochondria as 
an additional etiologic factor (Pipinos et al., 2006). The defective 
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mitochondrial network fragmentation are also observed in dam-
aged heart muscle, thus suggesting the significance of the mito-
chondrial reticular network in the etiology and progression of the 
disease (Shen et al., 2007).
The inexorable loss of terminally differentiated cardiomyocytes 
and the subsequent invasion of fibrotic tissue are pivotal to progres-
sion of heart diseases, especially ischemic and dilated cardiomyopa-
thies and congestive heart failure (Shen et al., 2007). During failure 
the heart decompensates because of an imbalance between energy 
production and use that leads to a state of energy deficit (Camara 
et al., 2010a). Abnormalities in energy transfer may occur in failing 
cardiac muscle and correlate with clinical symptoms and mortality 
(Murray et al., 2007). In general, the progression of heart failure 
can be characterized by diminished energy metabolism, poor Ca2+ 
handling, ROS generation, and apoptotic cell death. Alterations in 
mitochondrial function with dysregulation of mitochondrial bio-
genesis, and defects in ETC complexes I and III (Rosca et al., 2008), 
have been long suspected in heart failure. Indeed, therapies aimed 
at protecting mitochondrial function have shown some promise in 
heart failure patients and animal models of heart failure (Murray 
et al., 2007). For example, in mouse hearts exposed to chronic 
systolic pressure overload induced by transverse aortic constriction, 
the PGC-1α−/− knockout caused moderate but significant decreases 
in MnSOD and TRX2, with subsequent increases in oxidative stress 
markers, e.g., 4-HNE. Furthermore, treatment with the MnSOD 
mimetic MnTMPyP significantly reduced the transverse aortic 
constriction-induced left ventricular hypertrophy and dysfunc-
tion in PGC-1α−/− deficient mice (Lu et al., 2010).
The mitochondrial content and hence oxidative capacity of 
cardiac muscle cells are diminished in heart failure (Garnier et al., 
2003). The result is limited work capacity in the failing heart due to 
limited free mitochondrial energy (Ochiai et al., 2001; Gong et al., 
2003). Indeed, in mitochondria isolated from patients exhibiting 
severe cardiomyopathies there is a significant decrease in state 3 
respiration and a lower respiratory control index (Sharov et al., 
2000). Thus the altered metabolic pattern observed in heart failure 
has a clear impact on the energetic state of the heart. The potential 
consequences of a diminished energetic state include an impaired 
ability of the heart to work and respond to acute and chronic 
stresses (Camara et al., 2010b).
Although the idea of treating metabolic cardiac dysfunction is 
not new, the targeting of mitochondria has garnered significant 
interest recently. Cardiac metabolic homeostasis was summarized 
near the beginning of this review. The failing heart is character-
ized by enhanced glycolysis, impaired pyruvate oxidation, and 
reduced FA oxidation. Glycolysis generates pyruvate and if this 
pyruvate cannot be utilized by PDH to fuel OxPhos only 2 ATP 
molecules/glucose are realized. As discussed above, PDH is regu-
lated by multiple factors including PDH kinase (PDK) and PDH 
phosphatase (Beadle and Frenneaux, 2010); PDK, whose activ-
ity is low depending on NADH and acetyl-CoA coming from FA 
β-oxidation (Nediani et al., 2011), is thus a key regulator of glucose 
oxidation. Activated PDK phosphorylates and inhibits PDH and 
thereby blocks pyruvate uptake into mitochondria and prevents its 
oxidation. During acute ischemia, there is also a block at the level 
of PDH. It was reported that activation of PDK can lead to right 
function, the results from human studies have been singularly 
 disappointing (Cave et al., 2006; O’Connor and Gutterman, 2010). 
For example, instead of using antioxidants that are not targeted 
to sites of ROS (e.g., vitamins C and E), mitochondria-targeted 
ROS scavengers or other “mitochondriotropic” agents (discussed 
above) might be more effective (Cave et al., 2006; Dikalova et al., 
2010; O’Connor and Gutterman, 2010). Recent treatment strategies 
that target mitochondrial sources of ROS over cytosolic sources of 
ROS (O’Connor and Gutterman, 2010) have proven more effective 
in dampening endothelial dysfunction and minimizing vascular 
impairment (Dikalova et al., 2010). It is thought that the ability of 
targeted delivery in this case would also minimize the potential for 
untoward effects of other therapies that are less specific (Dikalova 
et al., 2010).
Other potential strategies include pathways that regulate mito-
chondrial biogenesis. As noted above, resveratrol is one such agent. 
Impaired mitochondrial endothelial cell function in a disease proc-
ess, e.g., diabetes, may impair bioenergetics, which could underlie 
a defect in endothelial paracrine factors essential for maintaining 
vascular tone (Csiszar et al., 2009a). Resveratrol has been shown 
to induce mitochondrial biogenesis in the aortas of diabetic mice 
and to reduce mitochondrial ROS; this suggests the potential for 
targeting endothelial mitochondria in metabolic diseases (Csiszar 
et al., 2009a,b). Interestingly, recent studies have demonstrated the 
presence of estrogen receptors on mitochondria and that estrogen 
stimulates increase ATP production while reducing ROS generation 
in cerebral arteries (Duckles et al., 2006). Estrogen also increases 
transcription of mitochondrial genes that encode subunits of com-
plex IV (Duckles et al., 2006). These effects could be significant in 
certain age-related cardiovascular diseases such as stroke (Duckles 
et al., 2006). Resveratrol and statin drugs also induce endothelial 
NOS to restore endothelial NO
 levels appropriate for vasodilata-
tion. This vascular response is central to the achievement of inte-
grated increases or redistribution of blood flow among specific 
vascular beds (Cave et al., 2006; Davidson and Duchen, 2007).
PotentIal for MItochondrIa-targeted strategIes for the 
faIlIng heart
Heart failure progressively limits the pumping capacity of the heart 
and endothelial and vascular dysfunction are important compo-
nents in this process (Davidson and Duchen, 2007) because of 
decreases in vascular diameter and compliance (coronary reserve) 
which reduces tolerance to exercise (Cave et al., 2006). Chronic 
heart failure occurs frequently as a consequence of longstanding 
hypertension or ischemic heart disease (Cave et al., 2006) and is a 
leading cause of morbidity and mortality in Western industrialized 
countries. Despite extensive studies, the fundamental mechanisms 
responsible for the development and progression of heart failure 
have yet to be fully elucidated (Tsutsui et al., 2006). A growing body 
of evidence supports a role for oxidative stress and redox signaling 
in the pathophysiology of heart failure (Cave et al., 2006). Indeed 
a number of recent studies have indicated that mitochondria are 
central to the pathophysiologic mechanism of the failing heart. 
Mitochondrial released ROS play a major role in mitochondrial 
bioenergetic dysfunction and contribute to myocardial apopto-
sis, which with cell necrosis and fibrotic cell invasion, underlie 
the anatomical progression of heart failure (Marin-Garcia and 
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and perhexiline have been shown to delay the development of 
terminal heart failure and attenuate the adverse hemodynamic 
changes (Abozguia et al., 2006). These drugs are known to activate 
expression of genes encoding key mitochondrial proteins involved 
in cardiac energy metabolism. For example, oxfenicine in heart 
failure has been shown to down regulate the transcription of CPT1 
and to prevent a decrease of TCA cycle enzyme activity (Abozguia 
et al., 2006). Other drugs such as trimetazidine, which blocks the 
key enzyme in FA oxidation, as well as ranolazine, are reported to 
directly attenuate β-oxidation enzyme activity and potentially other 
metabolic enzymes (Stanley et al., 1997; Bristow, 2000). Hence, the 
process of metabolic remodeling could serve as a target to restore 
metabolic flexibility and thereby facilitate improved myocardial 
contractility (Taegtmeyer et al., 2005; Kolwicz and Tian, 2009). 
This approach of optimizing energy substrate preference in the 
heart is a new and potentially promising approach to treat cardiac 
dysfunction associated with angina pectoris (Lam and Lopaschuk, 
2007) and other cardiac abnormalities.
As noted above, mitochondria isolated from failing hearts display 
increased ROS production in association with signs of oxidative 
stress-related damage due to accumulation of lipid peroxidation 
by-products and mutations or deletions of mtDNA (Ide et al., 2001; 
Burelle et al., 2009). Other studies show decreases in the expression 
and activity of catalase and MnSOD in heart failure (Laskowski 
and Russell, 2008). Evidence also shows increased mitochondrial 
membrane permeability and a consequent increase in release of 
cytochrome c and down stream pro-caspases; all of these factors 
indicate that the mitochondria-induced apoptotic pathway is a 
requirement to cardiomyocyte death by apoptosis (Burelle et al., 
2009). From these observations the importance of decreasing oxida-
tive and nitrosative stress by decreases in ROS and RNS generation 
and the successful use of antioxidant therapy in heart failure can 
not be overstated (Tsutsui et al., 2006). Indeed, ROS and RNS scav-
engers have been shown to attenuate the structural and functional 
abnormalities associated with heart failure in a rat model (Li et al., 
2009). In that study Li et al. (2009) reported that the antioxidant 
α-lipoic acid attenuated mitochondria-dependent apoptosis in dia-
betic cardiomyopathy. In addition, UCP levels are often decreased 
in animal models of heart failure and in human clinical samples 
(Laskowski and Russell, 2008). Targeting the UCPs therefore may 
represent a promising approach to managing heart failure.
PotentIal for treatIng MItochondrIa In cardIac I/r Injury
Some aspects of this subject were discussed in other sections 
and also were discussed extensively in two recent review articles 
(Chen et al., 2007; Camara et al., 2010b) so this topic will be only 
briefly addressed. I/R has been shown to result in mitochondrial 
dysfunction, so the importance of mitochondria as both targets 
and mediators of I/R injury is well recognized (Chen et al., 2007). 
During ischemia, ETC complex activities and the functions of 
ANT and CPT1 are depressed as a result of damage to cardiolipin 
and increased H+ leak, thereby compromising ∆Ψm and ATP sup-
ply (Paradies et al., 2009). During ischemia, anaerobic glycolysis 
partially generates the needed ATP with a concomitant increase 
in intracellular acidosis, but eventually impaired ATP-dependent 
ion pumps that are required to maintain ion homeostasis fail. 
ventricular dysfunction and that reduction of enzyme   function 
not only restores right ventricular function, but also enhances glu-
cose oxidation (Piao et al., 2010). Selected and precise control of 
these mitochondrial metabolic enzymes and glucose transporters 
(GLUT) represent possible therapeutic targets to modulate sub-
strate utilization (Beadle and Frenneaux, 2010). Indeed, a variety of 
metabolically targeted therapies have already been applied clinically 
in an attempt to improve cardiac metabolic function in human 
heart failure. These include, but are not limited to, an approach 
to reverse abnormal metabolism by stimulating PDH by inhibit-
ing PDK directly with dichloroacetate (DCA) and leelamine HCl, 
or indirectly with ranolazine and trimetazidine (Cadoudal et al., 
2008). DCA can restore ∆Ψm by inhibiting PDK and thereby acti-
vating PDH with a concomitant increase in intra-mitochondrial 
acetyl-CoA (Archer et al., 2008) (Figure 1). DCA has been safely 
used in children with inherited mitochondrial disorders (Bersin and 
Stacpoole, 1997) and lactic acidosis (Archer et al., 2008).
As discussed earlier, the adult healthy heart derives most of its 
energy from oxidation of FA, and FA oxidation strongly inhib-
its glucose oxidation; this is because acetyl-CoA derived from FA 
β-oxidation inhibits PDH activity so glycolysis is halted (Beadle and 
Frenneaux, 2010). Thus, by maintaining acetyl-CoA removal by FA 
β-oxidation, upregulation of PDK facilitates the continuous uptake 
of long chain fatty acyl-CoA (transformed from malonyl-CoA) into 
the mitochondrial matrix for oxidation, preventing their accumula-
tion in the cytoplasm, where they would exert toxic effects on car-
diac function (Nediani et al., 2011). However, despite its potential 
benefits, attempting to control β-oxidation of FA has numerous 
drawbacks and limitations. For example, although β-oxidation of 
FA produces more energy per carbon than glycolysis, it requires a 
higher consumption of O2 (Nediani et al., 2011).
In heart failure there appears to be a downregulation of genes 
controlling mitochondria biogenesis and of enzymes involved in 
FA oxidation (Nediani et al., 2011). The mitochondrial content 
and hence oxidative capacity of both skeletal and cardiac muscle 
cells are diminished in heart failure (Camara et al., 2010a), i.e., 
“starvation in the land of plenty.” However, the concept that FAs 
are bad for contractile function in the failing or diseased heart is 
challenged by other studies. For example, recent reports show that 
decreased FA oxidation during heart failure could be maladaptive 
(Cheng et al., 2004), and that increasing FA availability aids the 
failing heart (Duda et al., 2008; Muoio and Newgard, 2008). In 
this case, patients with dilated cardiomyopathy challenged with 
acute FA depletion demonstrated enhanced glucose oxidation but 
decreased cardiac work and efficiency (Tuunanen et al., 2006a,b). A 
crucial distinction between physiological and pathological cardiac 
remodeling (the later being a process ultimately progressing to 
heart failure) is the ability of the heart to match workload with an 
increased ATP production (see earlier discussion).
In an attempt to increase the efficiency of energy production 
in the failing heart, several drugs that inhibit FA oxidation and 
thereby allow glycolysis and SLP have been subject to testing. For 
example, etomoxir, originally developed as an anti-diabetic drug 
to switch energy metabolism from FA to glucose by inhibiting the 
FA transporter CPT1, has been clinically tested for treatment of 
chronic heart failure (Wolf, 1992; Kerner et al., 1994). However, 
long-term use of this drug is associated with toxicity and ironically, 
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suggest drugs that scavenge ROS may be more protective when 
administered on reperfusion, whereas blockers of ETC are more 
effective when given just before ischemia. Thus a potentially effec-
tive combination may be the selective administration of the differ-
ently acting drugs either before or after ischemia.
Other viable strategies that may work by modulating mitochon-
drial bioenergetics include the use of putative K+ channel agonists 
like NS1619 (discussed above) and uncouplers like DNP (Aldakkak 
et al., 2010; Sedlic et al., 2010b). Sedlic et al. (2010b) reported 
recently that isoflurane, like DNP, may protect cardiomyocytes in 
part via a mild decrease in ∆Ψm, which attenuated ROS production 
under stress and led to a delay in mPTP opening. Overexpression 
of UCPs in mice as well as chemical uncoupling of mitochondria in 
rats markedly reduced infarct volume following focal cerebral I/R 
(Duckles et al., 2006). However, clinical use of chemical uncoupling 
(e.g., DNP) has been limited by its toxicity (Camara et al., 2010b).
ModulatIon of tca cycle functIon as a PotentIal strategy to 
Protect MItochondrIa durIng I/r Injury
It has been suggested that glycolytically derived ATP is preferentially 
used to activate Ca2+ uptake into the ER by Ca2+ ATPase and to acti-
vate the Na+/K+ ATPase that prevents intracellular Na+ accumulation 
during ischemia (Beadle and Frenneaux, 2010). As discussed earlier, 
limited O2 availability during ischemia or hypoxia leads to a shift 
to glucose metabolism from mitochondrial OxPhos to cytosolic 
substrate level phosphorylation (SLP; anaerobic glycolysis); but 
prolonged ischemia leads to accumulation of lactic acid and deple-
tion of NAD+. To sustain glycolysis under prolonged anaerobic con-
ditions, lactate is excreted from the cell as a waste product. In this 
scenario, when mitochondrial function is compromised and ∆Ψm is 
reduced as in I/R, F0/F1 ATP synthase acts in reverse thereby hydro-
lyzing ATP in an attempt to reestablish ∆Ψm. In this case cytosolic 
ATP is consumed to pump H+ out of the matrix to attempt to restore 
∆Ψm; however, this is counterproductive for ATP-dependent cel-
lular processes, e.g., contraction/relaxation of myofibrils and for 
establishing cellular ionic homeostasis. In addition, restoration of 
∆Ψm may cause further matrix Ca2+ accumulation, which could lead 
to the perpetual and vicious cycle of cellular injury.
A novel concept in mitochondria-mediated cytoprotection is 
that enhanced SLP within the matrix (in contrast to cytosolic SLP 
from pyruvate) represents an endogenous rescue mechanism that 
supports the reversal of the F0F1 ATP synthase to maintain ∆Ψm 
while preserving cytosolic ATP. The matrix contains several enzyme 
sites capable of SLP; these include α-ketoglutarate dehydrogenase 
(Schwimmer et al., 2005) and succinyl-CoA synthase (SULCA). 
SUCLA is an enzyme that catalyzes the reversible conversion of 
succinyl-CoA and ADP or GDP to ATP or GTP (Kibbey et al., 
2007; Phillips et al., 2009). Hence, this could represent a source 
of ATP during ischemia, primarily by SLP (Camara et al., 2010a). 
Therefore, activation of these pathways could be crucial in periods 
of energy deprivation when complex V reverts to ATP consumption 
to maintain ∆Ψm as observed during I/R. In this way, cytosolic ATP 
levels from glycolysis might be preserved for maintaining the opera-
tion of ATP-dependent ion exchangers, e.g., Na+/K+ ATPase and 
Ca2+ ATPase, needed to maintain cellular cytosolic ion   gradients, 
while reverse ATP synthase at complex V supports, at least in part, 
Intracellular acidosis drives the Na+/H+ exchanger and this leads 
to increased intracellular [Na+] and a subsequent increase in intra-
cellular [Ca2+] after activation of the Na+/Ca+ exchanger in reverse 
mode. These alterations in cytosolic [Na+] and [Ca2+] also induce 
dysregulation of ion homeostasis in mitochondria resulting in 
mCa2+ overload (discussed above), which in turn results in mito-
chondrial depolarization that helps to limit further Ca2+ uptake via 
the CaU. Upon reperfusion however, repolarization of ∆Ψm coupled 
with increased cytosolic Ca2+ leads to a further increase in mCa2+ 
load via the CaU. With recovery of matrix pH (less acidic), low ATP 
levels, and a high Pi, on reperfusion, opening of the mPTP can occur. 
Thus, CsA and other mPTP inhibitors may lead to cardioprotec-
tion, but only if administered on reperfusion (Duchen, 2004). Five 
potential strategic approaches to protect mitochondria against car-
diac I/R injury are given in the following five sections (not discussed 
in our previous comprehensive review article (Camara et al., 2010a).
attenuatIon of MItochondrIal bIoenergetIcs as a PotentIal 
strategy to Protect agaInst I/r Injury
Many studies now show that increases in mitochondrial ROS and 
m[Ca2+] occur nearly simultaneously during ischemia (Vanden 
Hoek et al., 1997; Kevin et al., 2003; Riess et al., 2004; Stowe et al., 
2006; Camara et al., 2007; Aldakkak et al., 2008a,b) and that their 
reduction on reperfusion are indicative of protection. A pioneering 
study by Ganote et al. (1976) showed that inhibiting mitochon-
drial respiration could decrease contraction band formation and 
attenuate enzyme release during reoxygenation; they suggested 
that resumption of mitochondrial metabolism during reoxy-
genation could initially lead to deleterious consequences (Ganote 
et al., 1976). Either restriction of oxidative metabolism during the 
early reperfusion period, use of a hypoxic reperfusate (Kasamaki 
et al., 1997; Serviddio et al., 2005), or inhibition of ETC activity 
(Ambrosio et al., 1993), attenuated mitochondrial and cardiac dam-
age as evidenced by decreased cardiac function and accumulation 
of oxidatively damaged lipids. In a recent insightful review, Burwell 
and Brookes (2008) proposed the concept of “a more gradual wake-
up of mitochondrial function” to protect the myocardium from a 
burst of ROS and mCa2+ overload following I/R. This concept of 
gradual awakening on reperfusion is based on the premise that 
reversible inhibition of metabolism by blocking ETC complexes 
and glycolysis, and the slow reintroduction of electrons to the ETC, 
will reduce damage (Burwell and Brookes, 2008).
Many findings support the physiologic significance of excess 
mitochondrial ROS production in cardiac injury during reper-
fusion (Chen et al., 2007). With knowledge of some of the endpoints 
of cardiac injury there are now a variety of strategies to target mito-
chondria that are postulated to interrupt the link between mito-
chondrial damage during ischemia and mitochondria-mediated 
damage during reperfusion. Interestingly, we have observed prelim-
inarily that resveratrol, a ROS scavenger (Bastianetto et al., 2000), 
is more effective in protecting against I/R injury when adminis-
tered briefly on reperfusion, whereas ranolazine, the anti-anginal 
agent believed to reversibly inhibit complex I (Wyatt et al., 1995), 
was more effective against I/R injury when given briefly before 
ischemia (Aldakkak et al., 2009). Consistent with our observation 
with resveratrol in the isolated beating heart, Morin et al. (2003a) 
reported that resveratrol was more effective when administered 
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the heart, and like NO
,  it competitively inhibits O2 binding to 
complex IV, an effect that could promote myocardial cell survival 
during I/R (Bian et al., 2006; Lefer, 2007). Considered a poisonous 
gas at high concentrations, H2S is being recognized as an inorganic 
mediator with a potentially broad therapeutic potential (Baumgart 
et al., 2009). It could develop as a useful mediator of cardiovas-
cular homeostasis and cytoprotection. For example, H2S has been 
implicated in IPC cardioprotection via activation of both mitoKATP 
and sarcolemmal KATP channels; the exogenous H2S donor, NaHS, 
was shown to increase cell viability and to improve cardiac func-
tion during I/R (Bian et al., 2006); 5-HD abolished the protective 
effects of H2S (Baumgart et al., 2009). Another possible mechanism 
of protection by H2S is scavenging of ROS, by which it is believed 
to reduce arrhythmias during I/R (Bian et al., 2006). Similar cyto-
protective effects against oxidative stress have been observed in 
the brain where H2S protected neurons from oxidative stress by 
increasing the production of the antioxidant GSH (Kimura and 
Kimura, 2004). As a reducing agent, H2S may react with H2O2 and 
in this way scavenges ROS (Kimura and Kimura, 2004). However, 
the preferred route of therapeutic administration of H2S remains 
unclear.
  CO, like  NO
 and H2S, reversibly binds to the reduced complex 
IV where it competes with O2; CO may block O2 binding at complex 
IV in vivo (Zuckerbraun et al., 2007) and lead to cardioprotection 
against I/R injury, whereas Na azide, a cyanide containing com-
pound which also inhibits complex IV, was found to be ineffective 
in protecting the heart (Chen et al., 2010). Taken together, Chen 
et al. (2010) posits that there are inconsistencies regarding poten-
tial cardioprotection provided by complex IV inhibition. It may 
be that CO has other cytoprotective effects other than binding to 
complex IV. Indeed, in I/R, CO has been reported to increase ATP 
and GTP levels to maintain efficient energy utilization within the 
heart during the ischemic period (Lavitrano et al., 2004), which 
correlates to a greater ease by which the heart can generate force on 
reperfusion and minimize the incidence of fibrillation. Although 
the cause–effect relationship of CO with nucleotide concentrations 
is unclear, this metabolic modulation to protect the heart may be 
analogous to SLP-induced protection discussed previously. CO 
could also provide protection by preserving mitochondrial NADH, 
i.e., decrease oxidation of the reduced redox state, via its action 
on the ETC. The increase in NADH may reflect the possibility of 
decreased O2 consumption, resulting in an overall lower metabolic 
state and a reduction in appearance in apoptotic markers (Lavitrano 
et al., 2004). Endogenous CO generated by overexpression of heme 
oxygenase (HO)-1 was shown to stimulate MnSOD and generate 
H2O2, which in turn activated signaling molecules that lead to mito-
chondrial biogenesis (Piantadosi et al., 2008) and cardioprotection.
Interestingly, hydrogen gas (H2) has been proposed as a potential 
therapeutic agent with both anti-apoptotic and antioxidant features 
(Wood and Gladwin, 2007). Inhaled H2 gas can reach its target 
rapidly and provide protection against I/R (Hayashida et al., 2008). 
Thus H2 gas may be a promising strategy to mitigate I/R injury 
(Hayashida et al., 2008); but its use is limited by its highly explosive 
nature (Baumgart et al., 2009). All together, these studies provide 
a rationale for targeting mitochondria with low concentrations 
of gases that compete with O2 at complex IV, although as noted, 
the ∆Ψm. Therefore, cells may be salvaged as long as matrix SLP 
is able to provide ATP for use by complex V and by limiting the 
consumption of cytosolic ATP. Increasing the generation of matrix 
SLP may be a worthwhile, but temporary, strategy to mitigate mito-
chondrial dysfunction at times of impaired OxPhos. For example, 
overexpression or stimulation of SUCLA at a time of severe energy 
deficit may provide the needed ATP for mitochondrial preservation 
while sparing cytosolic ATP. Indeed, the putative mitoKATP channel 
agonist diazoxide may in part mediate protection by facilitating 
the binding of IF1, an endogenous regulator of F0F1 ATP synthase 
activity. Upon binding to complex V, IF1 blocks ATP synthase-
mediated ATP hydrolysis. In this way diazoxide could contribute 
to cardioprotection by preserving ATP during ischemia (Szewczyk 
et al., 2010).
ModulatIon of MItochondrIal ros generatIon as a PotentIal 
ProtectIve strategy durIng I/r Injury
Some aspects of this topic have been discussed earlier. Nonetheless, 
the association of O2
−  generation with I/R injury has made the 
development of antioxidants for therapeutic uses a plausible goal 
(Camara et al., 2010b). Therapeutic strategies to limit the rate of 
mitochondrial ROS generation or to increase the rate of ROS scav-
enging may be useful adjuvants to conventional therapies designed 
to protect the heart from I/R damage. We reported that administer-
ing a cocktail of mitochondrial scavengers (MnTBAP + glutathione 
+ catalase) prior to cold cardiac ischemia and warm reperfusion 
provided protection against mCa2+ overload and ROS produc-
tion and that this helped to preserve cardiac function (Camara 
et al., 2007). Artificial antioxidants such as SOD mimetics may be 
more potent than their natural counterparts, but their usefulness 
in clinical trials has not been determined (Muravchick and Levy, 
2006; Schapira, 2006). Needless to say, mitochondria-targeted ROS 
scavengers, such as ubiquinone and vitamin E, have shown some 
efficacy against cell damage associated with I/R injury. However, 
clinical trials using α-tocopherol (vitamin E), ascorbate (vitamin 
C), CoQ, and α-lipoic acid, have so far yielded ambiguous results 
(Camara et al., 2010b).
ModulatIon of gaseous sIgnalIng Molecules as a PotentIal 
ProtectIve strategy durIng I/r Injury
In addition to the endogenous enzymes synthesizing or releas-
ing  NO
 and O2
−, carbon monoxide (CO) and hydrogen sulfide 
(H2S) gases are also present in small amounts; they share many of 
the “friends-and-foe” characteristics of ROS and RNS (Baumgart 
et al., 2009). The role of NO
 has been discussed before in several 
sections and a detailed discussion of its role in cardioprotection 
can be found in our recent comprehensive articles (Stowe and 
Camara, 2009; Camara et al., 2010b), and will not be discussed 
further here. As gaseous second messengers, they also share some 
common biological targets, for example heme-proteins and KATP 
channels (Burwell et al., 2009). At physiologic concentrations CO 
and H2S may help to protect against many pathologic conditions 
including cardiovascular diseases. At higher concentrations, how-
ever, these gases are toxic with deleterious effects on the cell (Lefer, 
2007). A recent review article discusses the interplay between the 
gases at the level of mitochondrial complexes (Cooper and Brown, 
2008; Calvert et al., 2010).
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 from nitrosyl 
hemoglobin or myoglobin (Lohr et al., 2009). NIR-induced release 
of  NO
 might contribute to protection from reperfusion injury 
through actions on mitochondria and NO
-dependent signaling 
pathways. As noted above, an inhibitory effect of NO
 on ETC, 
particularly complexes I and IV, has been suggested to increase 
cellular viability in myocardial I/R injury by decreasing ROS gen-
eration during reperfusion (Hendgen-Cotta et al., 2008). Although 
NOS produces the bulk of NO
,  there is increasing interest in 
NOS independent generation of NO
 in vivo, particularly during 
hypoxia or anoxia, where low O2 tensions limit NOS activity and 
when the nitrite reductase activity of myoglobin and hemoglobin 
are highest (Gladwin and Kim-Shapiro, 2008). Interventions such 
as NIR that can increase NO
 bioavailability in a localized manner 
have significant therapeutic potential against heart disease without 
systemic side effects. Thus, the effect of NIR on the heart, and 
specifically on mitochondria, may depend on a delicate balance 
between stimulation and attenuation of mitochondrial metabolism.
lIMItatIons and conclusIon
As mitochondria are the most prominent source of intracellular ROS 
and RNS, they have been implicated in both defensive and offen-
sive aspects of the cell; but selective targeting of mitochondria with 
mitochondrial-targeted agents is likely to pose a quandary. Targeting 
mitochondria for therapeutic purposes poses a dilemma of how 
to protect, while at the same time, preserve the normal aspects of 
cellular functions that maintain viability. This quandary has been 
observed by Muravchick and Levy (2006) in a recent review article 
noting that, “therapeutic strategies that suppress or block the effects 
of putative pro-apoptotic agents may produce unintended inter-
ruptions of other cell functions and actually compromise viability.”
The aim of this review was to provide and summarize a growing 
body of evidence that mitochondria are intimately involved in cell 
survival and cell death and indeed in the etiology of cardiovascular 
diseases. This role renders mitochondria as unique targets for phar-
macological and non-pharmacological interventions. Currently, 
most efforts along these lines focus on preventing the mitochon-
drial oxidative damage that arises from ischemic or hypoxic con-
ditions. Examples of mitochondria-targeted maneuvers include: 
decreasing mPTP opening; decreasing ∆Ψm to reduce O2
− produc-
tion; moderate inhibition of complexes upstream of complex IV 
to reduce ROS production from complex III; limiting cytosolic 
ATP consumption during cell distress with increased matrix SLP; 
and increasing signaling gas molecules with, for instance, photo-
biomodulation therapy. In addition, mitochondria are targets for 
gene therapy in case of diseases caused by mutations of mtDNA 
or nuclear DNA (Wojtczak and Zablocki, 2008). The timing, con-
ditions of drug deliver, and drug concentration, will be crucial 
in assessing whether the treatment is beneficial or deleterious to 
mitochondrial function during and after cell injury.
It is evident that much attention has been focused on develop-
ing mitochondria-targeted drugs that may accumulate in mito-
chondria without affecting other parts of the cell. Therefore, 
novel approaches with more tissue specific mitochondria-targeted 
approaches or interventions that will furnish a greater efficacy and 
selectivity with fewer undesirable effects are being pursued. Use 
of mitochondriotropic drugs seems to be the most promising 
this may also be detrimental if administered at the inappropriate 
time and concentration. The defined physiological role of these 
gases makes them potential pharmacological candidates to target 
mitochondria in the treatment of cardiovascular diseases. Specific 
overexpression of those enzymes that generate some of these gases 
could be a feasible approach to mitigating some disease states, par-
ticularly in high energy consuming organs.
ProtectIng cardIac MItochondrIa wIth near Infrared lIght 
durIng cardIac I/r Injury
Mitochondria are sensitive targets for therapy with red light. Low 
energy photon irradiation by light in the far red to near infrared 
spectral range (630–1000 nm; NIR) emitted using low energy lasers 
or light emitting diode arrays (LED) has been found to provide 
good cardioprotection. In experimental models of myocardial inf-
arction low energy lasers (803 nm) reduced infarct size 50–70% 
4–6 weeks after permanent occlusion of the left descending coro-
nary artery in rats and dogs (Oron et al., 2001). Low-level laser 
application up-regulated inducible NOS and vascular endothelial 
growth factor and these changes were associated with cardioprotec-
tion and enhanced angiogenesis (Tuby et al., 2006).
We demonstrated recently that acute application of NIR 
(670 nm) at the point of reperfusion or reoxygenation resulted in 
a significant decrease in infarct size, or protection of cardiomyo-
cytes, respectively (Lohr et al., 2009; Zhang et al., 2009). Indices 
of apoptosis, including caspase 3 activity, annexin binding, and 
the release of cytochrome c from mitochondria into the cytosol, 
were decreased after NIR treatment. NIR increased NO
 levels in 
cardiomyocytes, and the protective effect of NIR was completely 
reversed by the NO
 scavenger carboxy-PTIO and by oxyhemo-
globin, but only partially blocked by the NOS inhibitor l-NMMA. 
Mitochondrial metabolism, measured by ATP synthase activity, was 
increased by NIR, and NO
-induced inhibition of O2 consump-
tion with substrates for complex I or complex IV was reversed by 
exposure to NIR (Zhang et al., 2009).
Mitochondrial cytochromes have been proposed as photoaccep-
tors for NIR light energy and mitochondrial redox changes have 
been proposed as potential mediators of the biological effects of 
NIR (Hallen et al., 1993; Hallen and Brzezinski, 1994; Wong-Riley 
et al., 2005). The action spectrum of NIR light for stimulation of 
cytochrome c oxidase activity parallels the NIR absorption spec-
trum of the oxidized form of complex IV (Karu et al., 2004). NIR 
increased mitochondrial metabolism, including cytochrome c oxi-
dase activity and elevated cellular ATP content (Karu et al., 1995). 
Interestingly, NIR reversed the toxic effects of KCN, an irreversible 
inhibitor of complex IV, in primary neurons (Wong-Riley et al., 
2005) and improved retinal function in an animal model of mito-
chondrial dysfunction induced by methanol-derived formate, a 
reversible cytochrome c oxidase inhibitor (Eells et al., 2004).
The mechanism behind this metabolic enhancement of chal-
lenged mitochondria through NIR remains controversial. Changes 
in the redox properties and acceleration of e− transfer at the center 
of complex IV have been suggested as well as enhanced NO
 release 
(Karu, 2008). The direct actions of light reversal of NO
 mediated 
complex IV inhibition, with its resulting increase in respiration and 
ATP production, could be effective in ameliorating reperfusion 
injury. In contrast, we demonstrated recently, both in purified 
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